{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 745, 'offsetInEndSection': 917, 'text': 'Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33941934'}, {'offsetInBeginSection': 1266, 'offsetInEndSection': 1452, 'text': 'Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36375644'}]\n\n\n                 'Which splicing factors have been associated with alternative splicing in PLN R14del hearts?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Srrm4\", \"Nova1\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 620, 'offsetInEndSection': 678, 'text': ' 64% deletions, 18% duplications and 18% point mutations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31381525'}, {'offsetInBeginSection': 926, 'offsetInEndSection': 1241, 'text': 'Of these, 406 (70.5%) were exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%). Small mutations were identified in 105 cases (18.2%), most being nonsense/frameshift types (75.2%). Mutations in splice sites, however, were relatively frequent (20%). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26284620'}, {'offsetInBeginSection': 440, 'offsetInEndSection': 524, 'text': 'gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6% (76/720)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21402533'}, {'offsetInBeginSection': 526, 'offsetInEndSection': 737, 'text': 'The rate of deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion patients; meanwhile, the rate of gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21402533'}, {'offsetInBeginSection': 738, 'offsetInEndSection': 862, 'text': 'In all the patients with gene deletion and duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD, 9.4% (44/467).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21402533'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620649'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620649'}, {'offsetInBeginSection': 419, 'offsetInEndSection': 703, 'text': 'While in earlier studies equal mutation rates in males and females had been reported, a breakdown by mutation types can better explain the sex ratio of mutations: Point mutations and duplications arise preferentially during spermatogenesis whereas deletions mostly arise in oogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23620649'}, {'offsetInBeginSection': 388, 'offsetInEndSection': 1129, 'text': 'l spectrum. This information is extremely beneficial for basic scientific research, genetic diagnosis, trial planning, clinical care, and gene therapy.METHODS: We collected data from 1400 patients (1042 patients with confirmed unrelated Duchenne muscular dystrophy [DMD] or Becker muscular dystrophy [BMD]) registered in the Chinese Genetic Disease Registry from March 2012 to August 2017 and analyzed the genetic mutational characteristics of these patients.RESULTS: Large deletions were the most frequent type of mutation (72.2%), followed by nonsense mutations (11.9%), exon duplications (8.8%), small deletions (3.0%), splice-site mutations (2.1%), small insertions (1.3%), missense mutations (0.6%), and a combination mutation of a dele', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29973226'}, {'offsetInBeginSection': 706, 'offsetInEndSection': 831, 'text': 'Deletions were the most common mutation type (256, 79%), followed by point mutations (45, 13.9%) and duplications (23, 7.1%).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35064276'}]\n\n\n                 'What are the most common mutation types in Duchenne muscular Dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"deletions\", \"exonic deldetions\", \"gene deletions\", \"deletion mutant\", \"duplications\", \"exonic duplications\", \"gene duplications\", \"point mutations\", \"deletion/duplication complex rearrangement\", \"nonsense/frameshift mutations\", \"mutations in splice sites\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 155, 'offsetInEndSection': 272, 'text': ' Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. T', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35130356'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 236, 'text': 'Neuropathic pain (NP) is a main feature of Fabry disease (FD) as consequence of small fiber neuropathy. Restless legs syndrome (RLS) in FD was not described, but it is an important feature in other small fiber neuropathies', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17948213'}, {'offsetInBeginSection': 13, 'offsetInEndSection': 184, 'text': 'mall fiber neuropathy (SFN) can be associated with autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (TS-HDS) antigen.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34698404'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 234, 'text': 'Up to 50% of small fiber neuropathy (SFN) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR-3) have been implicated in half of these cases', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36005471'}, {'offsetInBeginSection': 683, 'offsetInEndSection': 961, 'text': 'an the patients without SFN. Restless leg syndrome was also more frequently observed in patients with SFN, who had pain aggravated at rest that improved by moving.CONCLUSIONS: These findings are in favor of the sensitization of relatively spared large A\u03b2-fibers and second-order', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30247738'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Small fiber neuropathies (SFN) comprise a clinical syndrome typically associated with acral burning pain, where the pathophysiological processes affect the thinly myelinated A-delta and the unmyelinated C nerve fibers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30125923'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 210, 'text': 'Small fibre neuropathy (SFN), a condition dominated by neuropathic pain, is frequently encountered in clinical practise either as prevalent manifestation of more diffuse neuropathy or distinct nosologic entity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18524793'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Neuropathic pain is a characteristic feature of small fiber neuropathy (SFN), which in 18% of the cases is caused by genetic variants in voltage-gated sodium ion channels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36430572'}, {'offsetInBeginSection': 240, 'offsetInEndSection': 466, 'text': 'SFN was defined by the presence of suggestive sensory painful symptoms with normal nerve conduction studies and abnormal neurophysiologic tests for small nerve fibers or a low intraepidermal nerve fiber density at skin biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23982054'}, {'offsetInBeginSection': 94, 'offsetInEndSection': 222, 'text': 'SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30569495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 222, 'text': 'Small-fiber neuropathy (SFN) is a disorder of thinly myelinated A\u03b4 and unmyelinated C fibers. SFN is clinically dominated by neuropathic pain and autonomic complaints, leading to a significant reduction in quality of life.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30569495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 336, 'text': 'INTRODUCTION: Small fiber neuropathy (SFN) is a heterogeneous group of disorders affecting thin myelinated A\u03b4 and unmyelinated C fibers. Common symptoms include neuropathic pain and autonomic disturbances, and the typical clinical presentation is that of a length-dependent polyneuropathy, although other distributions could be present.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32654574'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 452, 'text': 'Small fiber neuropathy (SFN) is a peripheral nervous system disease due to affection of A-delta or C-fibers in a proximal, distal, or diffuse distribution. Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. Though uniform diagnostic criteria are unavailable, most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35130356'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 480, 'text': 'Small fibre neuropathies are a heterogeneous group of disorders affecting thinly myelinated A\u03b4-fibres and unmyelinated C-fibres. Although multiple causes of small nerve fibre degeneration have been reported, including via genetic mutations, the cause of small fibre neuropathy remains unknown in up to 50% of cases. The typical clinical presentation of small fibre neuropathy is that of a symmetrical, length-dependent polyneuropathy associated with sensory or autonomic symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29029847'}]\n\n\n                 'What are the main clinical features of small-fiber neuropathy (SFN)?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"pain\", \"sensory disturbance\", \"autonomic dysfunction\", \"restless leg syndrome\", \"autoantibodies\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 706, 'offsetInEndSection': 1045, 'text': ' In relation to clinical trials, in the last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31603849'}, {'offsetInBeginSection': 646, 'offsetInEndSection': 788, 'text': 'Several promising gene therapies are currently under investigation. These include gene replacement, exon skipping, suppression of stop codons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29351004'}, {'offsetInBeginSection': 789, 'offsetInEndSection': 947, 'text': 'More recently, a promising gene editing tool referred to as CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29351004'}, {'offsetInBeginSection': 271, 'offsetInEndSection': 561, 'text': 'Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34175043'}, {'offsetInBeginSection': 522, 'offsetInEndSection': 742, 'text': 'We recently showed that antisense oligoribonucleotide-mediated skipping of exon 46 efficiently induced dystrophin synthesis in cultured muscle cells from Duchenne muscular dystrophy patients carrying an exon 45 deletion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206800'}, {'offsetInBeginSection': 1125, 'offsetInEndSection': 1429, 'text': 'The success of induced exon skipping has spawned a number of \"fusion therapies\", including vector-mediated dystrophin exon skipping and ex vivo viral delivery of splice-switching antisense molecules into myogenic stem cells, followed by implantation, which may address long term oligomer delivery issues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20041827'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 273, 'text': 'Several clinical trials have recently demonstrated that oligonucleotide-based drugs induced targeted exon skipping in dystrophin pre-mRNA in Duchenne muscular dystrophy patients, resulting in novel expression of a truncated but functional isoform of the dystrophin protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22846203'}, {'offsetInBeginSection': 516, 'offsetInEndSection': 715, 'text': 'These strategies include gene replacement with adeno-associated virus, exon skipping with antisense oligonucleotides, and mutation suppression with compounds that \"read through\" stop codon mutations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23328943'}, {'offsetInBeginSection': 150, 'offsetInEndSection': 398, 'text': 'There are several promising genetic approaches, including viral delivery of the missing dystrophin gene, read-through of translation stop codons, exon skipping to restore the reading frame and increased expression of the compensatory utrophin gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23609411'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 418, 'text': 'So far, there is no effective treatment but new gene-based therapies are currently being developed with particular noted advances in using conventional gene replacement strategies, RNA-based approaches, or cell-based gene therapy with a main focus on Duchenne muscular dystrophy (DMD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19527108'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18228186'}, {'offsetInBeginSection': 450, 'offsetInEndSection': 762, 'text': \"The first viral-mediated gene transfer for any muscle disease was carried out at Columbus Children's Research Institute and Ohio State University for limb girdle muscular dystrophy type 2D, and the first viral-mediated trial of gene transfer for Duchenne muscular dystrophy is under way at the same institutions.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17846262'}, {'offsetInBeginSection': 271, 'offsetInEndSection': 562, 'text': 'Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34175043'}, {'offsetInBeginSection': 742, 'offsetInEndSection': 1174, 'text': \"Of all novel molecular interventions currently being investigated for Duchenne muscular dystrophy, perhaps the most promising method aiming to restore dystrophin expression to diseased cells is known as 'exon skipping' or splice-modulation, whereby antisense oligonucleotides eliminate the deleterious effects of DMD mutations by modulating dystrophin pre-messenger RNA splicing, such that functional dystrophin protein is produced.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20150322'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 94, 'text': 'Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206800'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Several new approaches to gene therapy for the muscular dystrophies involve oligonucleotides as targeting vectors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206797'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 448, 'text': 'gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17846262'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 257, 'text': 'rophy gene which abort dystrophin synthesis. We have explored a gene correction therapy aimed at restoration of the reading frame in Duchenne muscular', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206800'}, {'offsetInBeginSection': 359, 'offsetInEndSection': 579, 'text': 'on gene replacement and gene/expression repair, including exon-skipping, vector-mediated gene therapy and cell therapy. Therapeutic strategies for different forms of muscular dystrophy are discussed, with an emphasis on ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23387802'}]\n\n\n                 'Which gene therapies are under investigation for Duchenne muscular dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"gene replacement\", \"exon skipping\", \"suppression of stop codons\", \"CRISPR/Cas9\", \"Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 237, 'offsetInEndSection': 435, 'text': ' Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 456, 'offsetInEndSection': 769, 'text': ' According to the 2021 World Health Organization classification, the three risk types included (1) low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (IDH)-mutant, and 1p/19q-codeleted; (2) intermediate-risk, expecting astrocytoma, IDH-mutant; and (3) high-risk, expecting glioblastoma, IDH-wildtype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35587830'}, {'offsetInBeginSection': 238, 'offsetInEndSection': 436, 'text': 'Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 1213, 'offsetInEndSection': 1456, 'text': 'thogenesis and prognosis. Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocitrate dehydrogenase (IDH) mutant; oligodendroglioma, IDH mutant and 1p/19q codeleted; and gl', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006639'}, {'offsetInBeginSection': 437, 'offsetInEndSection': 666, 'text': 'This review briefly discusses two tumor types: astrocytoma, IDH-mutant, and oligodendroglioma, IDH-mutant and 1p/19q codeleted, with emphasis on relevant changes in their classification and defining molecular genetic alterations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 201, 'offsetInEndSection': 490, 'text': 'Since brainstem biopsies are rarely performed, these tumours are commonly classified according to their MR imaging characteristics into 4 subgroups: (a) diffuse intrinsic low-grade gliomas, (b) enhancing malignant gliomas, (c) focal tectal gliomas and (d) exophytic gliomas/other subtypes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25641008'}, {'offsetInBeginSection': 1566, 'offsetInEndSection': 2019, 'text': 'C\\u2009>\\u20090.5, k\\u2009>\\u20090.6, p\\u2009<\\u20090.001). IBGS type-I, type-II, and type-III gliomas had good specificity in identifying IDHmut 1p19q-codel oligodendroglioma (training - 97%, validation - 85%); IDHmut 1p19q non-codel astrocytoma (training - 80%, validation - 85.9%); and IDHwt glioblastoma (training - 76.5%, validation- 87.3%) respectively (p-value\\u2009<\\u20090.01).CONCLUSIONS: Imaging-based stratification of adult diffuse gliomas predicted patient survival and correlate', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35876874'}, {'offsetInBeginSection': 119, 'offsetInEndSection': 340, 'text': 'In the new WHO classification 2021, adult-type diffuse astrocytic gliomas subdivide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299937'}, {'offsetInBeginSection': 415, 'offsetInEndSection': 776, 'text': 'Recent genetic studies have revealed that the major categories of gliomas, such as circumscribe astrocytomas, infiltrating astrocytomas/oligodendrogliomas, and glioblastoma, roughly correspond to major genetic alterations, including isocitrate dehydrogenases (IDHs) 1/2 mutations, TP53 mutations, co-deletion of chromosome arms 1p/19q, and BRAF mutation/fusion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25744348'}, {'offsetInBeginSection': 151, 'offsetInEndSection': 590, 'text': \"This improves diagnostic accuracy and prognostication: oligo-astrocytoma no longer exists as a clinical entity; isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted oligodendroglioma is a smaller category with better prognosis; IDH wild-type 'low-grade' glioma has a much poorer prognosis; and glioblastoma is divided into IDH mutant (with an better prognosis than pre-2016 glioblastoma) and IDH wild type (with a poorer prognosis).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31175262'}, {'offsetInBeginSection': 203, 'offsetInEndSection': 414, 'text': 'A four-tiered WHO grading scheme has been successfully applied to a spectrum of diffusely infiltrative astrocytomas, but it is not fully applicable to other gliomas, including oligodendrogliomas and ependymomas.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25744348'}, {'offsetInBeginSection': 262, 'offsetInEndSection': 435, 'text': 'This has resulted in a major revision of the WHO classification, which is now for adult diffuse glioma centered around isocitrate dehydrogenase (IDH) and 1p/19q diagnostics.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28339700'}, {'offsetInBeginSection': 247, 'offsetInEndSection': 370, 'text': 'The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16700618'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 370, 'text': ' The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16700618'}, {'offsetInBeginSection': 609, 'offsetInEndSection': 759, 'text': 'ssion, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopathological and histopatho', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34729052'}, {'offsetInBeginSection': 198, 'offsetInEndSection': 348, 'text': 'vide into isocitrate dehydrogenase (IDH)-mutant astrocytoma, IDH-mutant and 1p/19q-codeleted oligodendroglioma, and IDH-wildtype glioblastoma. The T2-', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36299937'}, {'offsetInBeginSection': 293, 'offsetInEndSection': 443, 'text': 'include astrocytoma, isocitrate dehydrogenase (IDH)-mutant, oligodendroglioma, IDH-mutant and 1p/19q codeleted, and glioblastoma, IDH-wildtype. This r', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562130'}, {'offsetInBeginSection': 494, 'offsetInEndSection': 644, 'text': 'hese changes has been the division of adult astrocytomas into IDH-wildtype and IDH-mutant categories in addition to histologic grade as part of the ma', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32640746'}, {'offsetInBeginSection': 148, 'offsetInEndSection': 363, 'text': 'O classification, five main molecular subgroups of adult diffuse gliomas can be distinguished based on the 1p/19q codeletion, isocitrate dehydrogenase (IDH), and histone H3.3 mutation status. In the future, this cla', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30148717'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 467, 'text': 'Adult gliomas are most often infiltrative. The World Health Organization (WHO) has classed them into three major groups according to the presomptive cell of origin: astrocytoma, oligodendroglioma and mixed oligoastrocytoma. Depending on the presence or absence of a small number of signs of anaplasia (mitosis, nuclear atypia, cell density, microvascular proliferation and necrosis) the WHO distinguishes grade II (LGG), III (anaplastic), and IV (glioblastomas, GBM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21889777'}]\n\n\n                 'What are the  types/categories of adult diffuse gliomas.'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"astrocytoma\", \"oligodendroglioma\", \"glioblastoma\", \"isocitrate dehydrogenase (IDH)-mutant,\", \"1p/19q codeleted\", \"IDH-wildtype\", \"glioblastoma, IDH wildtype\", \"ependyoma\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 663, 'offsetInEndSection': 994, 'text': 'They combine two different monospecific antigen-binding regions that target CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab) format. The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35928819'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'Mosunetuzumab (Lunsumio\u00ae), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35947358'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'BACKGROUND: Mosunetuzumab is a CD20\\u2009\u00d7\\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. I', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35803286'}, {'offsetInBeginSection': 655, 'offsetInEndSection': 774, 'text': 'However, several CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab emerged recently. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35182296'}]\n\n\n                 'What are the targets of Mosunetuzumab?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"CD20\", \"CD3\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 876, 'offsetInEndSection': 1640, 'text': 'Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) for patients randomized to pembrolizumab compared with chemotherapy. In KEYNOTE-024, patients with previously untreated mNSCLC who received pembrolizumab (200 mg intravenously [IV] every 3 weeks) had a statistically significant improvement in OS (hazard ratio [HR] 0.60; 95% confidence interval [CI]: 0.41-0.89; p\\u2009=\\u2009.005), and significant improvement in PFS (HR 0.50; 95% CI: 0.37-0.68; p\\u2009<\\u2009.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing chemotherapy received pembrolizumab IV 2 mg/kg, 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513'}]\n\n\n                 'On which two clinical trials was the approval of Keytruda based?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"KEYNOTE-024\", \"KEYNOTE-010\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Cholestasis of pregnancy is the commonest liver disease unique to pregnancy and is characterized by pruritus in the mother in late pregnancy, without any skin rashes. This is accompanied by an elevation of the serum bile acids. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10385057'}, {'offsetInBeginSection': 302, 'offsetInEndSection': 656, 'text': 'diagnosis of liver disease when conventional liver function test such as SGOT, alkaline phosphatase, bilirubin and albumin are still normal. Serum bile acid determinations have been shown to be particularly useful in the diagnosis of alcoholic liver disease, drug-induced liver disease, viral hepatitis and cholestasis of intra- and extrahepatic origin. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/493809'}, {'offsetInBeginSection': 1692, 'offsetInEndSection': 1967, 'text': 'CONCLUSIONS: Plasma bilirubin seems to be the best liver function test in distinguishing patients with malignant bile duct strictures from those with bile duct stones. This routine test should receive more attention in clinical decision-making than has previously been given.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 1390, 'offsetInEndSection': 1682, 'text': ' bilirubin proved to be the best laboratory test in differentiating patients (p=0.001 vs. alkaline phosphatase, p<0.001 vs. alanine aminotransferase and p<0.001 vs. gamma-glutamyltransferase). With a plasma bilirubin cutoff value of 145 micromol/L, four out of five patients were categorized ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 923, 'offsetInEndSection': 1138, 'text': 'Plasma bilirubin (p<0.001), alkaline phosphatase (p<0.001) and alanine aminotransferase (p=0.040) levels were significantly higher in patients with malignant bile duct strictures than in those with bile duct stones.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 769, 'offsetInEndSection': 913, 'text': 'Plasma alkaline phosphatase, gamma-glutamyltransferase, alanine aminotransferase and bilirubin values were determined in the morning before ERCP', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17163822'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 280, 'text': 'Intrahepatic cholestasis of pregnancy (ICP) is the most frequent pregnancy-specific liver disease. It is characterized by pruritus and an accompanying elevation of serum bile acid concentrations and/or alanine aminotransferase (ALT), which are the key parameters in the diagnosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33896963'}, {'offsetInBeginSection': 836, 'offsetInEndSection': 994, 'text': ' The liver function test revealed elevated levels of serum total bile acids, bilirubin, and transaminases; however, the \u03b3-glutamyl transferase level was norma', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27530795'}, {'offsetInBeginSection': 252, 'offsetInEndSection': 480, 'text': 'Cholestasis is usually suspected clinically when a patient presenting with jaundice or pruritus is found to have an elevation in serum alkaline phosphatase activity disproportionate to increases in serum aminotransferase levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7583073'}, {'offsetInBeginSection': 2007, 'offsetInEndSection': 2202, 'text': 'The biochemical parameters traditionally used for the assessment of extrahepatic cholestasis, AP, GGT, and bilirubin, do not support the diagnosis of intrahepatic cholestasis caused by cirrhosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9794902'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 553, 'text': 'ase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests should be termed liver chemistries or liver tests. Hepatocellular injury is defined as disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels. Cholestatic injury is defined as disproportionate elevation of alkaline phosphatase level as compared with AST and ALT levels. Th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27995906'}]\n\n\n                 'The diagnosis of cholestasis is based on the elevations seen in what liver function tests?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Alkaline phosphatase\", \"ALP\", \"Alanine aminotransferase\", \"ALT\", \"Aspartate Aminotransferase\", \"AST\", \"Bilirubin\", \"Serum Bile Acids\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35993765'}, {'offsetInBeginSection': 59, 'offsetInEndSection': 134, 'text': 'Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35914259'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904210'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 199, 'text': 'BACKGROUND: Intramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35904210'}]\n\n\n                 'Which drugs are included in the AZD7442?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"tixagevimab\", \"cilgavimab\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 233, 'offsetInEndSection': 324, 'text': '2 different programmed cell death protein 1 (PD-1) inhibitors, Nivolumab and Pembrolizumab.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32984529'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 306, 'text': 'The first monoclonal antibodies against the immune checkpoint programmed death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26822752'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 289, 'text': 'e programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29222273'}, {'offsetInBeginSection': 361, 'offsetInEndSection': 570, 'text': 'The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25682878'}, {'offsetInBeginSection': 320, 'offsetInEndSection': 597, 'text': 'Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29357948'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 230, 'text': 'Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28923211'}, {'offsetInBeginSection': 531, 'offsetInEndSection': 677, 'text': 'The US Food and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27058852'}, {'offsetInBeginSection': 361, 'offsetInEndSection': 569, 'text': 'The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25682878'}, {'offsetInBeginSection': 244, 'offsetInEndSection': 380, 'text': 'other tumors. In 2014, nivolumab and pembrolizumab, two checkpoint inhibitors binding to PD-1, were approved for the treatment of metast', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33686894'}, {'offsetInBeginSection': 648, 'offsetInEndSection': 867, 'text': ' Pembrolizumab is one of the first immune checkpoint inhibitors approved by the FDA to treat NSCLC and is currently the only immunotherapy drug approved for first-line treatment of NSCLC in immune checkpoint inhibitors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32388240'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 313, 'text': ' A PD-1 antibody, nivolumab, was the first of these agents to be approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, as a new cancer drug for melanoma, in July 2014.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27795534'}, {'offsetInBeginSection': 447, 'offsetInEndSection': 597, 'text': 's paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29357948'}, {'offsetInBeginSection': 360, 'offsetInEndSection': 510, 'text': 'ministration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully h', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30304963'}]\n\n\n                 'What were the first 2 PD-1 inhibitors approved by the FDA in 2014?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Pembrolizumab\", \"Keytruda\", \"Nivolumab\", \"Opdivo\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36362876'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 273, 'text': 'Ornithine transcarbamylase deficiency (OTC-D) is an X-linked metabolic disease and the most common urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36217298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3826955'}, {'offsetInBeginSection': 342, 'offsetInEndSection': 589, 'text': 'extreme irritability (100 percent), episodic vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3945292'}, {'offsetInBeginSection': 230, 'offsetInEndSection': 359, 'text': 'Ornithine transcarbamylase deficiency causes vomiting, lethargy, hyperventilation, and even death, mainly in the neonatal period.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17845164'}]\n\n\n                 'What are the clinical symptoms of an ornithine transcarbamylase deficiency?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"seizures\", \"developmental delay\", \"hyperammonaemic encephalopathy\", \"hyperammonemia,\", \"delayed physical growth\", \"Stage II coma\", \"ataxia\", \"protein avoidance\", \"vomiting\", \"lethargy\", \"irritabilty\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'Eagle-Barrett Syndrome (EBS) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35429431'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'BACKGROUND: Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome (EGBRS), is a rare congenital disease characterized by deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35526214'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Prune Belly syndrome (PBS) or Eagle-Barrett syndrome is an anatomo-radiological syndrome consisting of a complex and rare malformation characterized by the following triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30560020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 223, 'text': 'Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome, is a rare congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29174092'}]\n\n\n                 'What is the triad of the Eagle-Barrett Syndrome?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"absent or defective abdominal wall muscles\", \"urinary tract abnormalities\", \"bilateral cryptorchidism\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 400, 'offsetInEndSection': 508, 'text': 'Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26771990'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 168, 'text': 'he Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome:', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33572131'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 296, 'text': 'This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt\u00ae), asenapine (Saphris\u00ae), and lurasidone (Latuda\u00ae), all of which have been approved by the U.S. Food and Drug Administration since 2009. Each is indicated for the treatment of schizophrenia, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21446639'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 265, 'text': 'Lurasidone (Latuda(\u00ae)), a benzisothiazole derivative antipsychotic, is approved in the USA and Canada for the treatment of adults with major depressive episodes (MDE) associated with bipolar I disorder; this article reviews studies of lurasidone in this indication.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25698146'}, {'offsetInBeginSection': 400, 'offsetInEndSection': 509, 'text': 'Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26771990'}, {'offsetInBeginSection': 453, 'offsetInEndSection': 610, 'text': 'Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26316760'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 236, 'text': 'The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13-17 years of age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29962579'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Lurasidone is one of several antipsychotics approved in the recent past by the US FDA for the treatment of schizophrenia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22364325'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 304, 'text': 'Lurasidone is a novel benzoisothiazol antipsychotic that has recently been approved for the treatment of schizophrenia in the U.S. Like many other second-generation antipsychotics, it has a high affinity for dopamine D(2) and serotonin 5-HT(2A) receptors as well as a high affinity for 5-HT(7) receptors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22146224'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 326, 'text': 'Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26755968'}, {'offsetInBeginSection': 207, 'offsetInEndSection': 333, 'text': 'Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25852975'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Lurasidone is a second-generation antipsychotic newly approved by the U.S. Food and Drug Administration for the treatment of schizophrenia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21177242'}, {'offsetInBeginSection': 99, 'offsetInEndSection': 276, 'text': 'cide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24955752'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 93, 'text': 'Update on the development of lurasidone as a treatment for patients with acute schizophrenia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22675261'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 53, 'text': 'Lurasidone: a new treatment option for schizophrenia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22146224'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 188, 'text': 'Lurasidone is an important antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder, with an oral bioavailability of 9-19% owing to its poor aqueous solubility.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34534629'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Background: Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia in 2010.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34860899'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32124704'}]\n\n\n                 'What is the first indication for lurasidone?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"schizophrenia\", \"Bipolar depression.\", \"Tourette syndrome\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 184, 'offsetInEndSection': 289, 'text': 'Whole-exome sequencing was utilized to detect disease-causing variants in 40 MLPA-negative DMD patients. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35218518'}, {'offsetInBeginSection': 421, 'offsetInEndSection': 524, 'text': 'WES analysis revealed that nonsense variant was the most common type in our study (23/36 of the cases).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35218518'}, {'offsetInBeginSection': 818, 'offsetInEndSection': 992, 'text': '. The present study has demonstrated the importance of performing WES to detect disease-causing point mutations in MLPA-negative DMD patients and to identify carrier females.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35218518'}, {'offsetInBeginSection': 146, 'offsetInEndSection': 299, 'text': 'Whole exome sequencing (WES) and multiple ligation-dependent probe amplification (MLPA) were used to detect potential deletions in the STS and DMD genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35929940'}, {'offsetInBeginSection': 462, 'offsetInEndSection': 619, 'text': 'The newborns with retest positive result were recalled again for serum creatine kinase (CK) and multiplex ligation-dependent probe amplification (MLPA) test.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36281417'}, {'offsetInBeginSection': 620, 'offsetInEndSection': 684, 'text': 'Whole exon sequencing was performed when MLPA test was negative.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36281417'}, {'offsetInBeginSection': 247, 'offsetInEndSection': 446, 'text': ' In this study we aimed to determine the mutational spectrum of multiplex ligation-dependent probe amplification (MLPA)-negative muscular dystrophy patients in Pakistan using whole-exome sequencing. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33734897'}, {'offsetInBeginSection': 1665, 'offsetInEndSection': 1803, 'text': 'Whole-exome sequencing identified a nonsense variant in Pakistani muscular dystrophy patients, which is amenable to treatment by Ataluren ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33734897'}, {'offsetInBeginSection': 220, 'offsetInEndSection': 345, 'text': ' We used the combination of multiplex ligation-dependent probe amplification (MLPA) and sequencing analysis of the DMD gene. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34327855'}, {'offsetInBeginSection': 422, 'offsetInEndSection': 592, 'text': 'We performed DNA tests in 152 patients, checking first exon deletion/duplication by MLPA, and subsequently, if negative, samples were sequenced to detect point mutations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34327855'}, {'offsetInBeginSection': 387, 'offsetInEndSection': 628, 'text': 'The strategy for molecular diagnostic testing for DMD involves initial screening for deletions/duplications using microarray-based comparative genomic hybridization (array-CGH) followed by full-sequence analysis of DMD for sequence variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25271841'}, {'offsetInBeginSection': 762, 'offsetInEndSection': 1045, 'text': 'Thus, NGS-based multigene panel testing for muscular dystrophy-associated genes or clinical exome sequencing rather than targeted DMD gene sequencing appears to be a more cost-effective testing modality with better diagnostic yield, for MLPA-negative patients with the DMD phenotype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33552634'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 416, 'text': 'OBJECTIVE: To optimize the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).METHODS: Denaturing high-performance liquid chromatography (DHPLC), multiplex PCR (mPCR), sequencing and other molecular techniques were used in combination for molecular diagnosis of 8 cases diagnosed as DMD.RESULTS: Among the 8 cases, 4 have carried large deletions, 3 have point mutations, among ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26037351'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'BACKGROUND: Genetic testing for Duchenne/Becker muscular dystrophy (DMD/BMD) mutations initially involved multiplex polymerase chain reaction (mPCR), which targeted two mutation hotspots in the gene and detected deletions in aff', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24300647'}, {'offsetInBeginSection': 1080, 'offsetInEndSection': 1344, 'text': 'Most frequently performed first step diagnostic tests in Group I and Group II were muscle biopsy and MLPA.Our study reflects the change in the age at genetic diagnosis and diagnostic approach to nm-DMD depending on the advances and availability of genetic testing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30453357'}, {'offsetInBeginSection': 555, 'offsetInEndSection': 729, 'text': ' Dystrophin testing in muscle is the most sensitive test for identification of dystrophinopathy patients, although gene deletion studies can make the diagnosis in most cases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8745379'}, {'offsetInBeginSection': 572, 'offsetInEndSection': 713, 'text': 'Diagnostic use of Xp21 probes is now as necessary as EMG, muscle biopsy and serum CK assay for the definition of Duchenne muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2669113'}]\n\n\n                 'What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"MLPA\", \"Multiple Ligation-Dependent Probe Amplification\", \"WES\", \"Whole-Exome Sequencing\", \"target-NGS\", \"Next Generation Sequencing\", \"NGS\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 201, 'offsetInEndSection': 377, 'text': 'In most cases the condition initially presents with facial and proximal weakness of the upper limbs, but over the course of the disease involves lower limb and truncal muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 378, 'offsetInEndSection': 464, 'text': 'Weakness is progressive and frequently asymmetric, which is a hallmark of the disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 599, 'offsetInEndSection': 700, 'text': '5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 768, 'offsetInEndSection': 1340, 'text': ' patients with FSHD. Sponsors of treatments for FSHD patients should be aware of some of the common misconceptions associated with FSHD drug development with the goal of optimizing the chance to prove safety and efficacy for each potential treatment for FSHD in the clinical trial setting.RESULTS: Four major topics with potential clinical manifestations for patients with FSHD will be discussed related to muscle weakness, respiratory issues, animal models and prevalence.CONCLUSION: The authors offer multiple solutions to help counteract misconceptions with each scenar', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32008231'}, {'offsetInBeginSection': 465, 'offsetInEndSection': 700, 'text': 'Here we performed an analysis of 643 FSHD1 patients in the UK FSHD patient registry, investigating factors affecting rate of onset of 5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 848, 'offsetInEndSection': 1100, 'text': 'FAT1 lies near the critical locus involved in causing FSHD, and Fat1 mutant mice also show retinal vasculopathy, mimicking another symptom of FSHD, and showed abnormal inner ear patterning, predictive of deafness, reminiscent of another burden of FSHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23785297'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'RATIONALE: Early-onset facioscapulohumeral muscular dystrophy (FSHD) is defined as facial weakness before the age of 5 and shoulder weakness before the', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34964760'}, {'offsetInBeginSection': 1179, 'offsetInEndSection': 1471, 'text': 'A classical presentation (74%) and 3 facial sparing phenotypes: a mild presentation (5%) with later facial and periscapular involvement, an early shoulder presentation (10%) with accelerated periscapular weakness and an early foot presentation (9%) with accelerated foot dorsiflexor weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32327287'}, {'offsetInBeginSection': 1471, 'offsetInEndSection': 1774, 'text': 'Patients with FSHD also had reduced systemic antioxidative response molecules, such as low levels of zinc (a SOD cofactor), selenium (a GPx cofactor involved in the elimination of lipid peroxides), and vitamin C. Half of them had a low ratio of gamma/alpha tocopherol and higher ferritin concentrations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22796148'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'Facioscapulohumeral muscular dystrophy (FSHD) is characterized by progressive weakness and wasting of facial, shoulder-girdle and upper arm muscles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15050443'}, {'offsetInBeginSection': 122, 'offsetInEndSection': 483, 'text': 'Typically, FSHD patients present with a recognizable constellation of signs including weakness of facial, shoulder and pelvic girdle, humeral, and anterior foreleg muscles; preservation of some muscles including the deltoids; and other characteristic features including prominent scapular winging, anterior axillary folds, and horizontally positioned clavicles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11353419'}, {'offsetInBeginSection': 241, 'offsetInEndSection': 500, 'text': 'physiology. Typically, progressive skeletal muscle weakness becomes noticeable in the second or third decade of life, yet there are many individuals who are genetically FSHD but develop symptoms much later in life or remain relatively asymptomatic throughout ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32278354'}, {'offsetInBeginSection': 68, 'offsetInEndSection': 218, 'text': 't neuromuscular disorder characterized by progressive weakness of the facial, shoulder and upper arm muscles. The major gene involved has been mapped ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11592052'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'We report an 18-year-old female with facioscapulohumeral dystrophy (FSHD), who had sensorineural deafness, retinal vessel abnormality, mental retardation, and epilepsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1908258'}, {'offsetInBeginSection': 82, 'offsetInEndSection': 232, 'text': 'cular dystrophy characterized by progressive weakness and wasting of the facial, shoulder-girdle and upper arm muscles. The gene locus for FSHD is map', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12134683'}, {'offsetInBeginSection': 53, 'offsetInEndSection': 203, 'text': 'nherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles. FSHD is caused by chromatin relaxation of t', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34559225'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 234, 'text': 'PURPOSE: Severe manifestations of facioscapulohumeral dystrophy (FSHD) may be associated with sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and nocturnal hypoventilation (NH), but prevalence data are scarce', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31025273'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 374, 'text': 'Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10864616'}, {'offsetInBeginSection': 61, 'offsetInEndSection': 211, 'text': 'onset facioscapulohumeral muscular dystrophy (FSHD) present epilepsy and mental retardation. This suggests a functional involvement of central nervous', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14659411'}, {'offsetInBeginSection': 138, 'offsetInEndSection': 218, 'text': ' The major symptom of FSHD is progressive weakening and loss of skeletal muscles', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32008231'}, {'offsetInBeginSection': 35, 'offsetInEndSection': 185, 'text': 'phy (FSHD) is an autosomal dominant disorder characterized by progressive muscle weakness. Adenine nucleotide translocator 1 (ANT1), the only 4q35 gen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36030628'}, {'offsetInBeginSection': 258, 'offsetInEndSection': 408, 'text': 'l symptoms are extremely variable including facial sparing type, limb-girdle type, and distal myopathy type. Most of the FSHD patients have a deletion', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15050443'}]\n\n\n                 'Which are some symptoms of FSHD?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"facial weakness\", \"facial dorsiflexor\", \"proximal weakness of the upper limbs\", \"periscapular dorsiflexor\", \"lower limb weakness\", \"hip girdle weakness\", \"foot dorsiflexor\", \"truncal muscles weakness\", \"asymmetric weakness\", \"hearing loss.\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 210, 'offsetInEndSection': 398, 'text': ' Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562158'}, {'offsetInBeginSection': 399, 'offsetInEndSection': 606, 'text': 'Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562158'}, {'offsetInBeginSection': 521, 'offsetInEndSection': 887, 'text': 'g more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 349, 'offsetInEndSection': 946, 'text': 'otypic correlates. This article discusses the epidemiology, clinical features, and diagnosis of these disorders.RECENT FINDINGS: Some important recent advancements include (1) a much greater understanding of the pathogenetic pathways underlying facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1; (2) the publication of diagnostic and treatment guidelines for Duchenne muscular dystrophy; and (3) further clarification of the many genetic muscle disorders presenting a limb-girdle pattern of weakness.SUMMARY: Muscular dystrophies are genetic, progressive, degenerative disorders', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24305447'}, {'offsetInBeginSection': 127, 'offsetInEndSection': 519, 'text': 'The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrophin; myotonic dystrophy type 1, which results from an expanded trinucleotide repeat in the myotonic dystrophy protein kinase gene; and facioscapulohumeral dystrophy, which is associated with contractions in the subtelomeric region of human chromosome 1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19555515'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 181, 'text': 'Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are the two most common adult muscular dystrophies and have progressive and often disabling manifestations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27734165'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 145, 'text': 'Duchenne Muscular Dystrophy (DMD), the most common form of muscular dystrophies, is characterized by progressive and generalized muscle weakness.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36121164'}, {'offsetInBeginSection': 676, 'offsetInEndSection': 914, 'text': \"re included in this study. 102 (27.8%) out of the 366 patients were affected by Duchenne muscular dystrophy (DMD), 42 (11.5%) by congenital muscular dystrophy (CMD), 42 (11.5%) by Charcot Marie Tooth disease (CMT) and 24 (6.5%) by Becker'\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32095889'}, {'offsetInBeginSection': 558, 'offsetInEndSection': 924, 'text': 'his article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 548, 'offsetInEndSection': 628, 'text': 'EAS COVERED: Duchenne muscular dystrophy is the most common muscular dystrophy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27340611'}, {'offsetInBeginSection': 333, 'offsetInEndSection': 420, 'text': 'Myotonic muscular dystrophy is the most common of the adult-onset muscular dystrophies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3728255'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29770119'}, {'offsetInBeginSection': 856, 'offsetInEndSection': 1063, 'text': 'We discuss the involvement of the immune system in the most common muscular dystrophy, Duchenne muscular dystrophy, and show that the immune system influences muscle death and fibrosis as disease progresses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30215857'}, {'offsetInBeginSection': 477, 'offsetInEndSection': 572, 'text': \"Duchenne's muscular dystrophy is the most common form of inherited muscle disease of childhood.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28427100'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, is a severe muscle disorder, causing muscle weakness, loss of independence, and premature death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35089797'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Duchenne muscular dystrophy (DMD), the most common and most severe form of all muscular dystrophies, leads to progressive muscle fiber necrosis, fibroblast proliferation, and growth of fibrous tissue and fat.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25955813'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Duchenne and Becker muscular dystrophies are the most common clinical forms of muscular dystrophies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24213305'}, {'offsetInBeginSection': 235, 'offsetInEndSection': 385, 'text': ' cause exercise intolerance to some degree. Here, we focus on Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, as a para', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23733645'}, {'offsetInBeginSection': 62, 'offsetInEndSection': 212, 'text': 'ied by progressive skeletal muscle weakness and degeneration. Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrop', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27073590'}, {'offsetInBeginSection': 36, 'offsetInEndSection': 186, 'text': ' debilitating disorders caused by progressive muscle wasting. Duchenne muscular dystrophy (DMD) is the most common type. DMD is a well-characterized g', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35360042'}]\n\n\n                 'What are the most common muscular dystrophies?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Congenital muscular dystrophies (CMD)\", \"dystroglycanopathies\", \"merosin-deficient CMD\", \"collagen VI-deficient CMD\", \"SELENON-related rigid spine muscular dystrophy\", \"LMNA-related CMD\", \"Childhood and adult-onset muscular dystrophies\", \"limb-girdle muscular dystrophies\", \"LGMD\", \"Emery-Dreifuss muscular dystrophy\", \"EDMD\", \"facioscapulohumeral muscular dystrophy\", \"FSHMD\", \"myotonic dystrophy\", \"Duchenne Muscular Dystrophy\", \"DMD\", \"Becker Muscular Dystrophy\", \"BMD\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 136, 'offsetInEndSection': 266, 'text': 'DM type 2 (DM2) is considered less severe than DM type 1 (DM1), but it is unknown whether this applies uniformly to all features. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35778789'}, {'offsetInBeginSection': 182, 'offsetInEndSection': 393, 'text': 'There are two genetically distinct types of myotonic dystrophy: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2), both dominantly inherited with significant overlap in clinical manifestations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35205411'}, {'offsetInBeginSection': 109, 'offsetInEndSection': 330, 'text': 'The unstable repeat expansions of (CTG)n or (CCTG)n in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy: (i) myotonic dystrophy type 1 (DM1) and (ii) myotonic dystrophy type 2 (DM2) respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23570879'}, {'offsetInBeginSection': 128, 'offsetInEndSection': 321, 'text': 'Congenital myotonic dystrophy (CDM1) and myotonic dystrophy of type 1 (DM1) or of type 2 (DM2) are caused by the expression of mutant RNAs containing expanded CUG or CCUG repeats, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21623381'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 125, 'text': 'Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29770119'}, {'offsetInBeginSection': 200, 'offsetInEndSection': 440, 'text': 'To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)(n) and (CCTG)(n), respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496635'}, {'offsetInBeginSection': 435, 'offsetInEndSection': 609, 'text': 'Myotonic dystrophies MD1 and MD2 are multisystem diseases with numerous symptoms and high interfamily variability, resulting from the fact that different organs are affected.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20514907'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': \"There are currently two clinically and molecularly defined forms of myotonic dystrophy: (1) myotonic dystrophy type 1 (DM1), also known as 'Steinert's disease'; and (2) myotonic dystrophy type 2 (DM2), also known as proximal myotonic myopathy.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20176601'}, {'offsetInBeginSection': 531, 'offsetInEndSection': 878, 'text': 'Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496635'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 139, 'text': 'Myotonic dystrophy types 1 (DM1) and 2 (DM2) are autosomal dominant, microsatellite repeat expansion disorders that affect muscle function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27727437'}, {'offsetInBeginSection': 123, 'offsetInEndSection': 480, 'text': \"There are two forms identified: myotonic dystrophy type 1 (DM1), caused by an expansion of a CTG repeat in the 3' untranslated region of the myotonin-protein kinase (DMPK) gene on chromosome 19, and myotonic dystrophy type 2 (DM2), caused by an expansion of a CCTG repeat in intron 1 of the cellular nucleic acid-binding protein (CNBP) gene on chromosome 3.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19360700'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 99, 'text': 'Myotonic dystrophy type 1 (DM1) and type II (DM2) are dominantly inherited multisystemic disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19632331'}, {'offsetInBeginSection': 512, 'offsetInEndSection': 748, 'text': ' For the enormous understanding of the molecular pathogenesis of myotonic dystrophy type 1 and myotonic dystrophy type 2, these diseases are now called \"spliceopathies\" and are mediated by a primary disorder of RNA rather than proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33458578'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 300, 'text': \"This review demonstrates genetic and phenotypic heterogeneity in all of the multisystemic myotonic disorders collectively called 'myotonic dystrophies' according to the new nomenclature: myotonic dystrophy type 1, myotonic dystrophy type 2, proximal myotonic myopathy and proximal myotonic dystrophy.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11073357'}, {'offsetInBeginSection': 65, 'offsetInEndSection': 215, 'text': 'progress in elucidating the disease mechanism in myotonic dystrophy type 1 and type 2.RECENT FINDINGS: Research on myotonic dystrophy has led to the r', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17885447'}, {'offsetInBeginSection': 203, 'offsetInEndSection': 326, 'text': 'The 2 major genetic forms of myotonic dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32067592'}, {'offsetInBeginSection': 901, 'offsetInEndSection': 1075, 'text': 'CENT FINDINGS: An active approach to screening and management of myotonic dystrophies type 1 and type 2 requires a multidisciplinary medical, rehabilitative and social team. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25121518'}, {'offsetInBeginSection': 30, 'offsetInEndSection': 180, 'text': 'onest adult muscular dystrophy. Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are often discussed jointly, and although they sha', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24435591'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 148, 'text': 'PURPOSE OF REVIEW: Myotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and genetic features in common', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25121518'}, {'offsetInBeginSection': 149, 'offsetInEndSection': 302, 'text': 'Two genetically distinct forms of DM are identified - type 1 (DM1), the classic form first described by Steinert, and type 2 (DM2), identified by Ricker.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20625963'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 149, 'text': 'Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders resulting from the expansion of (CTG)n nucleotide repeats in the DMPK gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35243403'}, {'offsetInBeginSection': 1613, 'offsetInEndSection': 1763, 'text': 'ers of subjects, sometimes even not separating Myotonic Dystrophy Type 1 from Type 2. But this heterogeneity may also support the current point of vie', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30186217'}, {'offsetInBeginSection': 1081, 'offsetInEndSection': 1241, 'text': 'Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22995693'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'BACKGROUND AND OBJECTIVE: Myotonic dystrophy types 1 and 2 are progressive multisystem genetic disorders whose core clinical feature is myotonia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34840883'}]\n\n\n                 'Which are the types of myotonic dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"myotonic dystrophy type 1 (DM1)\", \"myotonic dystrophy type 2 (DM2)\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 583, 'offsetInEndSection': 854, 'text': 'Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (FDA) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35954196'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag\u2122) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35543970'}, {'offsetInBeginSection': 201, 'offsetInEndSection': 377, 'text': 'DATA SOURCES: A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36268952'}]\n\n\n                 'What are the active components of Opdualag?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Nivolumab\", \"Relatimab\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 889, 'offsetInEndSection': 956, 'text': 'Distal hotspot exons 47, 48 and 50 were the commonly deleted exons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35359537'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 149, 'text': 'Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35897138'}, {'offsetInBeginSection': 1662, 'offsetInEndSection': 1803, 'text': 'We confirmed that del45-55 segregates a high proportion of benign phenotypes, severe cases, and isolated cardiac and cognitive presentations.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35897138'}, {'offsetInBeginSection': 218, 'offsetInEndSection': 285, 'text': 'In particular, exons 45-52 constitute a hotspot for DMD mutations. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33531685'}, {'offsetInBeginSection': 1099, 'offsetInEndSection': 1238, 'text': 'An exon deletion hotspot, located in exons 45-54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33101180'}, {'offsetInBeginSection': 383, 'offsetInEndSection': 563, 'text': 'In-frame exon skipping of dystrophin exons 45-55 represents a significant approach to treating DMD, as a large proportion of patients harbor mutations within this \"hotspot\" region.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29771942'}, {'offsetInBeginSection': 783, 'offsetInEndSection': 1045, 'text': 'Here, we provide an update on DMD genotype-phenotype associations using a global DMD database and further provide the rationale for multiple exon skipping development, particularly for exons 45\u207b55 skipping and an emerging therapeutic concept, exons 3\u207b9 skipping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30544634'}, {'offsetInBeginSection': 494, 'offsetInEndSection': 649, 'text': ' A deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene was detected, and dystrophin protein expression was \u223c15% that of control level.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27009627'}]\n\n\n                 'What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"exon 45-55\", \"exon 45-54\", \"exon 45-52\", \"exons 47, 48 and 50\", \"exons 3-9\", \"exon 3\", \"exon 3\", \"exon 4\", \"exon 5\", \"exon 6\", \"exon 7\", \"exon 8\", \"exon 9\", \"exon 45\", \"exon 51\", \"exon 44\", \"exon 47\", \"exon 48\", \"exon 49\", \"exon 50\", \"exon 51\", \"exon 55\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 751, 'offsetInEndSection': 922, 'text': 'In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24011979'}, {'offsetInBeginSection': 1199, 'offsetInEndSection': 1332, 'text': 'In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24011979'}, {'offsetInBeginSection': 159, 'offsetInEndSection': 270, 'text': 'Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16144755'}, {'offsetInBeginSection': 388, 'offsetInEndSection': 584, 'text': 'We describe a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure, thus facilitating and accelerating the standard Southern blot based DNA test.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16144755'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 215, 'text': 'The molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD) relies on detecting contractions of the unique D4Z4 repeat array at the chromosome 4q35 locus in the presence of a permissive 4q35A haplotype.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34384893'}, {'offsetInBeginSection': 1000, 'offsetInEndSection': 1108, 'text': 'The Southern blot analysis with DNA probe p13E-11 has created a valuable molecular diagnostic test for FSHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9192267'}, {'offsetInBeginSection': 239, 'offsetInEndSection': 385, 'text': 'The gene whose defect causes FSHD has not been identified, but molecular diagnosis can be made by analyzing D4Z4 repeat length on chromosome 4q35.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22109111'}, {'offsetInBeginSection': 277, 'offsetInEndSection': 456, 'text': 'Here, we present a comprehensive analysis of the currently used diagnostic methods (Southern blotting and molecular combing) against a new qPCR-based approach for FSHD1 diagnosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34071558'}, {'offsetInBeginSection': 719, 'offsetInEndSection': 889, 'text': 'llelic variant of chromosome 4. In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and h', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24011979'}, {'offsetInBeginSection': 552, 'offsetInEndSection': 780, 'text': 'In this report we describe a protocol that can be used for DNA testing in well defined familial cases or proven de novo cases, and in the differential diagnosis of muscular dystrophy patients clinically suspected of having FSHD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8825045'}, {'offsetInBeginSection': 451, 'offsetInEndSection': 663, 'text': 'A valuable molecular diagnostic test for FSHD has been created with the use of p13E-11 probe to detect the EcoR I/Bln I double digestion fragment which is usually smaller in FSHD patient than in normal indivdual.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11592052'}, {'offsetInBeginSection': 805, 'offsetInEndSection': 946, 'text': 'Molecular diagnosis for FSHD is usually offered with 98% accuracy but because of its complexity, a much more simple test would be preferable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11962336'}, {'offsetInBeginSection': 646, 'offsetInEndSection': 755, 'text': ' Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD without need for muscle biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21567298'}, {'offsetInBeginSection': 576, 'offsetInEndSection': 726, 'text': ' number of repetitive elements (D4Z4) on chromosome 4q35 (4qA allele). Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD wi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21567298'}, {'offsetInBeginSection': 1302, 'offsetInEndSection': 1452, 'text': 'and the homologous 10q26 regions were also detected.CONCLUSION: Molecular diagnosis of FSHD became a routine approach in Hungary thus supporting the w', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21920844'}, {'offsetInBeginSection': 418, 'offsetInEndSection': 568, 'text': '5.7+/-12.3 years (range: 26-72). The diagnosis of FSHD was confirmed by genetic tests. All patients underwent medical and neurological evaluations, su', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19501370'}]\n\n\n                 'Which diagnostic tests are used for the diagnosis of FSHD?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Southern blot based DNA test\", \"DNA test\", \"EMG\", \"muscle biopsy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 795, 'offsetInEndSection': 925, 'text': ' In DMD, there was a prevalence of 7.0% of ASDs, 18.0% of ADHD, 11.0% of depression, 24.0% of anxiety disorders, and 12.0% of OCD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35839922'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 287, 'text': 'To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35839922'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 143, 'text': 'Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders, and patients often present with autism spectrum disorder (ASD)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34148958'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 244, 'text': 'Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33741226'}, {'offsetInBeginSection': 107, 'offsetInEndSection': 243, 'text': 'Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33741226'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 268, 'text': 'Increased rates of clinically significant internalizing disorders (obsessive compulsive disorder, anxiety, and depression) have been demonstrated in males with Duchenne muscular dystrophy, and a Duchenne muscular dystrophy neuropsychiatric syndrome has been suggested.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29779439'}, {'offsetInBeginSection': 183, 'offsetInEndSection': 385, 'text': 'disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsi', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29795071'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 720, 'text': 'OBJECTIVE: To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).DATA SOURCES: MEDLINE (via PubMed), Scopus, Web of Science, and Cochrane Library from inception to November 2021.STUDY SELECTION: Observational studies of individuals with DMD or BMD that estimated the prevalence of ASDs, ADHD, depression, anxiety disorders, and OCD in each population.DATA EXTRACTION: A random-effects meta-analysis was performed on each outcome and each population (ie, DMD, BM', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35839922'}]\n\n\n                 'What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"autism spectrum disorders\", \"ASDs\", \"ASD\", \"autism\", \"attention-deficit hyperactivity disorder\", \"ADHD\", \"attention deficit disorder\", \"depression\", \"anxiety disorders\", \"obsessive-compulsive disorder\", \"OCD\", \"epilepsy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 164, 'offsetInEndSection': 369, 'text': 'Dupilumab, a monoclonal antibody targeting the interleukin (IL)-4 receptor alpha to inhibit IL-4 and IL-13 signaling, has recently been shown to significantly improve the condition of patients with CRSwNP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36214075'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor \u03b1, used in the treatment of atopic dermatitis (AD).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34358343'}, {'offsetInBeginSection': 711, 'offsetInEndSection': 976, 'text': 'The development of new therapies received great impetus by an ample research of the pathophysiological mechanisms, leading to a new era in the treatment of severe atopic eczema due to targeted treatments, e.g. the IL-4R alpha specific monoclonal antibody dupilumab.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34236520'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 136, 'text': 'BACKGROUND: The human monoclonal antibody dupilumab blocks interleukin (IL)-4 andIL-13, key and central drivers of type 2 inflammation. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33993501'}, {'offsetInBeginSection': 538, 'offsetInEndSection': 806, 'text': ' An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-R\u03b1) and the signaling pathways activated by interleukin (IL)-4 and IL-13. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33588666'}]\n\n\n                 'Which interleukins are affected by Dupilumab?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"interleukin-4\", \"interleukin-13\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 120, 'offsetInEndSection': 309, 'text': ' Current approaches to regeneration and tissue engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and signals, including morphogens and growth factors', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24710539'}, {'offsetInBeginSection': 514, 'offsetInEndSection': 732, 'text': ' Autologous cartilage regeneration is a cell-based therapy in which autogenous chondrocytes or other chondrogenic cells are cultured to constitute cartilaginous tissue according to the principles of tissue engineering.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19251544'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'Cartilage engineered from chondrocytes requires a scaffold to keep the cells in the cartilage defect and to act as a support for inducing hyaline cartilage formation ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17454427'}, {'offsetInBeginSection': 462, 'offsetInEndSection': 667, 'text': 'To address these challenges, the focus of gene therapy for bone and cartilage repair has shifted in recent years to the use of autologous cells, typically osteocytes or chondrocytes, or their progenitors, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19649985'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 151, 'text': 'Articular Cartilage Chondrocytes are more Advantageous for Generating Hyaline-like Cartilage than Mesenchymal Cells Isolated from Microfracture Repairs', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15256927'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 126, 'text': 'Influence of gel properties on neocartilage formation by auricular chondrocytes photoencapsulated in hyaluronic acid networks.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16482551'}, {'offsetInBeginSection': 238, 'offsetInEndSection': 307, 'text': 'affect neocartilage formation by encapsulated auricular chondrocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16482551'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'Transplanting human umbilical cord mesenchymal stem cells and hyaluronate hydrogel repairs cartilage of osteoarthritis in the minipig model.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30692826'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 156, 'text': 'Osteoarthritis (OA) is a chronic disease of degenerative joints. Mesenchymal stem cells (MSCs) have been used for cartilage regeneration in OA. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30692826'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 129, 'text': 'BACKGROUND: Mesenchymal stem cells (MSCs) and/or biological scaffolds have been used to regenerate articular cartilage with varia', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30603587'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 451, 'text': 'le success. In the present study we evaluated cartilage regeneration using a combination of bone marrow (BM)-MSCs, HyalofastTM and/or native cartilage tissue following full thickness surgical cartilage defect in rabbits.METHODS: Full-thickness surgical ablation of the medial-tibial cartilage was performed in New Zealand', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30603587'}, {'offsetInBeginSection': 80, 'offsetInEndSection': 604, 'text': 'as increased. Mesenchymal Stem Cells (MSCs) have been proposed to be an attractive alternative candidate in the tissue engineering of articular cartilage primarily due to its abundant source, reduced cartilage donor site morbidity, and strong capacity for proliferation and potential to differentiate toward a chondrogenic phenotype.AREAS COVERED: A current overview of human, in vivo, and in vitro evidence on the use of MSCs in cartilage tissue engineering.EXPERT OPINION: We demonstrate robust evidence that MSCs have the', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22784026'}, {'offsetInBeginSection': 1770, 'offsetInEndSection': 2248, 'text': 'In this article, we review the progress on stem cell therapies for arthritic disorders, focusing on the various stem cell populations previously used for cartilage regeneration, successful cases of stem cell therapies in muscle and hemopoietic disorders, some of the reasons why these other fields have been successful (i.e., \"lessons learned\" to be applied to OA stem cell therapy), and finally, novel potential sources of stem cells for regenerating damaged cartilage in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35711627'}, {'offsetInBeginSection': 466, 'offsetInEndSection': 623, 'text': 'Here, we provide an overview of the current status of cord blood cells and induced pluripotent stem cells derived from these cells in cartilage regeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30251563'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 161, 'text': 'Combination of Mesenchymal Stem Cells, Cartilage Pellet and Bioscaffold Supported Cartilage Regeneration of a Full Thickness Articular Surface Defect in Rabbits.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30603587'}, {'offsetInBeginSection': 309, 'offsetInEndSection': 417, 'text': 'The use of autologous mesenchymal stem cells (MSCs) for cartilage regeneration has been widely investigated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33607469'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'Bone marrow-derived mesenchymal stem cells (BMSCs) are a good cell source for regeneration of cartilage as they can migrate directly to the site of cartilage injury and differentiate into articular chondrocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24759682'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 422, 'text': 'Alginate microbeads containing adipose stem cells (ASCs) pretreated with chondrogenic media have been used successfully to regenerate hyaline cartilage in critical size defects in rat xiphoid suggesting that they may be used to treat defects in elastic cartilages such as the ear.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29766656'}, {'offsetInBeginSection': 106, 'offsetInEndSection': 254, 'text': 'Articular chondrocytes, cartilage progenitor cells, embryonic stem cells, and mesenchymal stem cells are candidate cells for cartilage regeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26000333'}, {'offsetInBeginSection': 957, 'offsetInEndSection': 1295, 'text': 'This review briefly summarizes chemokines and growth factors that induce recruitment, proliferation, and differentiation of endogenous progenitor cells, endogenous cell sources for regenerating cartilage, scaffolds for delivery of bioactive factors, and bioadhesive materials that are necessary to bring about endogenous cartilage repair.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26559963'}, {'offsetInBeginSection': 87, 'offsetInEndSection': 380, 'text': 'Mesenchymal stem cells derived from synovium have been shown to be a superior cell source for cartilage regeneration to those from other mesenchymal tissues due to their higher rates of colony formation, proliferation potential with autologous serum, and in vitro/vivo chondrogenic potentials.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21628803'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': '[Use of bone marrow mesenchymal stem cells for ex vivo cartilage regeneration].', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17333068'}, {'offsetInBeginSection': 216, 'offsetInEndSection': 319, 'text': 'Here we show resident fibrocartilage stem cells (FCSCs) can be used to regenerate and repair cartilage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27721375'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Exploiting endogenous fibrocartilage stem cells to regenerate cartilage and repair joint injury.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27721375'}, {'offsetInBeginSection': 684, 'offsetInEndSection': 821, 'text': 'Regenerated cartilage can be derived from various cell types, including chondrocytes, pluripotent stem cells, and mesenchymal stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637149'}, {'offsetInBeginSection': 208, 'offsetInEndSection': 372, 'text': 'There are several cell sources being investigated to promote cartilage regeneration: mature articular chondrocytes, chondrocyte progenitors, and various stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29018484'}, {'offsetInBeginSection': 328, 'offsetInEndSection': 669, 'text': 'In this study, we aimed to evaluate and compare the in vitro characteristics and chondrogenic capacity of some easily available adult cell sources for use in cartilage repair which includes: bone marrow-derived mesenchymal stem cells (MSC), adipose tissue-derived MSC, articular chondrocyte progenitors, and nasal septum-derived progenitors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26507473'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Chondrocytes or adult stem cells for cartilage repair: the indisputable role of growth factors.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21696723'}, {'offsetInBeginSection': 215, 'offsetInEndSection': 319, 'text': ' Here we show resident fibrocartilage stem cells (FCSCs) can be used to regenerate and repair cartilage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27721375'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 174, 'text': 'The use of mesenchymal stromal cells (MSCs) for tissue engineering of hyaline cartilage is a topical area of regenerative medicine that has already entered clinical practice.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34829895'}, {'offsetInBeginSection': 69, 'offsetInEndSection': 201, 'text': ' Currently, ex vivo expanded chondrocytes or bone marrow-derived mesenchymal stem cells are used to regenerate the damaged cartilage', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28129782'}, {'offsetInBeginSection': 612, 'offsetInEndSection': 758, 'text': 'In this investigation, we assessed the chondrogenic ability of human dental pulp stem cells (hDPSCs) to regenerate cartilage in vitro and in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28951745'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 219, 'text': 'Multipotent mesenchymal stromal cells (MSCs) are primitive cells capable of restoring damaged mesenchyme and with the ability to differentiate into mature cells of bone, cartilage, muscle, fat, nerve or fibrous tissues.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24726343'}]\n\n\n                 'What cells are used to regenerate cartilage?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"chondrocytes\", \"Stem cells\", \"progenitor\", \"Mesenchymal stem cells\", \"fibrocartilage stem cells\", \"Osteocytes\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 27, 'offsetInEndSection': 244, 'text': 'To evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36280258'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 107, 'text': 'Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36280258'}, {'offsetInBeginSection': 28, 'offsetInEndSection': 241, 'text': 'eurodegeneration and astrocytic activation are pathologic hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 132, 'text': 'Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 2219, 'offsetInEndSection': 2325, 'text': 'sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 2327, 'offsetInEndSection': 2487, 'text': 'Thus, sGFAP and sNfL levels may be used to stratify patients with progressive MS for clinical research studies and clinical trials and may inform clinical care.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36376097'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 350, 'text': 'Neurofilament light-chain (NfL) protein is a blood-based marker of neuroaxonal injury. We sought to (1) compare plasma NfL levels in children with chronic kidney disease (CKD) and healthy peers, (2) characterize the relationship between NfL level and kidney function, and (3) evaluate NfL as a predictor of abnormal brain structure in CKD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}, {'offsetInBeginSection': 1742, 'offsetInEndSection': 1928, 'text': 'Within the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decreased kidney function may be linked to abnormal neuronal integrity in pediatric CKD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}, {'offsetInBeginSection': 471, 'offsetInEndSection': 644, 'text': 'Using single-molecule array assays, we evaluated longitudinal changes of serum neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and GFAP/NfL levels.R', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34212756'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 118, 'text': 'Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34283286'}, {'offsetInBeginSection': 1394, 'offsetInEndSection': 1633, 'text': 'erum NfL and GFAP could be potential diagnostic biomarkers for BM in patients with lung cancer. We established a model that can provide individual diagnoses of BM. Higher NfL level may be associated with poor prognosis of patients with BM.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34283286'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 410, 'text': \" The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34313819'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 97, 'text': 'Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34313819'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 87, 'text': 'Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33893614'}, {'offsetInBeginSection': 1014, 'offsetInEndSection': 1122, 'text': 'NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33893614'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 134, 'text': ' The neurofilament light chain (NfL) has emerged as a versatile biomarker for CNS-diseases and is approaching clinical use.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33759425'}, {'offsetInBeginSection': 10, 'offsetInEndSection': 134, 'text': ': Serum neurofilament light (sNfL) chain is a promising biomarker reflecting neuro-axonal injury in multiple sclerosis (MS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658739'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658739'}, {'offsetInBeginSection': 1179, 'offsetInEndSection': 1352, 'text': 'Serum NfL concentration was the only factor associated with disease worsening, indicating that sNfL is a useful biomarker in MS that might be relevant in a clinical setting.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35658739'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 257, 'text': 'Patients with Langerhans cell histiocytosis (LCH) may develop progressive neurodegeneration in the central nervous system (ND-CNS-LCH). Neurofilament light protein (NFL) in cerebrospinal fluid (CSF) is a promising biomarker to detect and monitor ND-CNS-LCH.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35582775'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 100, 'text': 'Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35582775'}, {'offsetInBeginSection': 541, 'offsetInEndSection': 705, 'text': 'Thus, our results suggest that p-NFL may be used to screen for ND-CNS-LCH. Further studies are encouraged, including the role of p-NFL for monitoring of ND-CNS-LCH.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35582775'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35575811'}, {'offsetInBeginSection': 666, 'offsetInEndSection': 836, 'text': 'Circulating Neurofilament light chain (NfL) levels have been recognized as a sensitive prognostic and monitoring biomarker of neuroaxonal damage in various CNS disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35575811'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 147, 'text': 'Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35638376'}, {'offsetInBeginSection': 24, 'offsetInEndSection': 150, 'text': 'To investigate the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35638376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 709, 'text': \"BACKGROUND: A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD).METHODS: With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99\\xa0subjects with AD at the stage of mild cognitive impairment (MCI-AD; n\\u2009=\\u200925) or at the stage of early dementia (ADD; n\\u2009=\\u200933), and in nondemented controls (n\\u2009=\\u200941); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid \u03b2 (A\u03b2)1-42, A\u03b242/40, Tau, and pTau181), interpreted according to the Erla\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30055655'}, {'offsetInBeginSection': 110, 'offsetInEndSection': 418, 'text': 'The levels of neurofilament light chain (NfL) in both cerebrospinal fluid (CSF) and plasma have been related to degeneration in several neurodegenerative conditions including frontotemporal dementia (FTD) and NfL is currently considered as the most promising diagnostic and prognostic fluid biomarker in FTD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33108404'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': \"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.\", 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30055655'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': \"Neurofilament light chain (NfL) is a marker of brain atrophy and predictor of disease progression in rare diseases such as Huntington Disease, but also in more common neurological disorders such as Alzheimer's disease.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33636389'}, {'offsetInBeginSection': 1634, 'offsetInEndSection': 1715, 'text': 'In conclusion, NfL plasma levels are elevated during ECM confirming brain damage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35750882'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 114, 'text': 'Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35750882'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 277, 'text': 'Background: Neurofilament light chain (NfL) is an axonal cytoskeletal protein that is released into the extracellular space following neuronal or axonal injury associated with neurological conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and oth', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35959400'}, {'offsetInBeginSection': 191, 'offsetInEndSection': 345, 'text': ' Increased levels of circulating neurofilament light chain (NfL), a biomarker of neuro-axonal injury, have been observed in patients with severe COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35075461'}, {'offsetInBeginSection': 374, 'offsetInEndSection': 661, 'text': 'Our results shown that plasma NfL levels increased with an increase in cognitive impairment across the three groups of PD patients: PD with normal cognition (PD-NC), 17.9\\xa0\u00b1\\xa08.9\\xa0pg/ml; PD with mild cognitive impairment (PD-MCI),21.9\\xa0\u00b1\\xa010.3\\xa0pg/ml; and PD dementia (PDD), 35.7\\xa0\u00b1\\xa021.7\\xa0pg/ml.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34311152'}, {'offsetInBeginSection': 194, 'offsetInEndSection': 330, 'text': \" In Alzheimer's disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29630554'}, {'offsetInBeginSection': 1749, 'offsetInEndSection': 1846, 'text': 'the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decrea', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34274959'}]\n\n\n                 'Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"neuroaxonal damage in various CNS disordersNS disorders\", \"neurodegenerative diseases\", \"CNS disease\", \"radiologically isolated syndrome (RIS)\", \"Chronic Kidney Disease\", \"Brain Metastasis\", \"cancer\", \"The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS)\", \"Ataxia telangiectasia (A-T)\", \"Langerhans cell histiocytosis (LCH)\", \"Multiple Sclerosis\", \"acute and chronic inflammatory polyneuropathies\", \"ALS\", \"Amyotrophic Lateral Sclerosis\", \"Creutzfeldt Jacob syndrome\", \"progressive supranuclear palsy\", \"Alzheimer's Disease\", \"Parkinson's disease\", \"Myotonic dystrophy\", \"frontotemporal dementia\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': 'Accessible chromatin often represents gene regulatory elements, including promoters and enhancers, essential for gene expression. Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) is one of the most popular techniques to investigate chromatin accessibility across the genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36173566'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 767, 'text': 'Functional cis-regulatory elements (CREs) act as precise transcriptional switches for fine-tuning gene transcription. Identification of CREs is critical for understanding regulatory mechanisms of gene expression associated with various biological processes in eukaryotes. It is well known that CREs reside in open chromatin that exhibits hypersensitivity to enzyme cleavage and physical shearing. Currently, high-throughput methodologies, such as DNase-seq, ATAC-seq, and FAIRE-seq, have been widely applied in mapping open chromatin in various eukaryotic genomes. More recently, differential MNase (micrococcal nuclease) treatment has been successfully employed to map open chromatin in addition to profiling nucleosome landscape in both mammalian and plant species.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36264486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 331, 'text': \"Micrococcal nuclease (MNase) originating from Staphylococcus aureus is a calcium dependent ribo- and desoxyribonuclease which has endo- and exonucleolytic activity of low sequence preference. MNase is widely used to analyze nucleosome positions in chromatin by probing the enzyme's DNA accessibility in limited digestion reactions.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35796986'}, {'offsetInBeginSection': 1120, 'offsetInEndSection': 1384, 'text': 'In this review, we discuss techniques for determining DNA accessibility and nucleosome positioning (DNase-seq, FAIRE-seq, MNase-seq, and ATAC-seq) and techniques for detecting and functionally characterizing chromatin-bound proteins (ChIP-seq, DamID, and CUT&RUN).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31776829'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 520, 'text': 'Recent advancements in next-generation sequencing technologies and accompanying reductions in cost have led to an explosion of techniques to examine DNA accessibility and protein localization on chromatin genome-wide. Generally, accessible regions of chromatin are permissive for factor binding and are therefore hotspots for regulation of gene expression; conversely, genomic regions that are highly occupied by histone proteins are not permissive for factor binding and are less likely to be active regulatory regions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31776829'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'The ATAC-seq assay has emerged as the most useful, versatile, and widely adaptable method for profiling accessible chromatin regions and tracking the activity of cis-regulatory elements (cREs) in eukaryotes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33606259'}, {'offsetInBeginSection': 356, 'offsetInEndSection': 655, 'text': 'We have developed a method for profiling the accessibility of individual chromatin fibers, a single-molecule long-read accessible chromatin mapping sequencing assay (SMAC-seq), enabling the simultaneous, high-resolution, single-molecule assessment of chromatin states at multikilobase length scales.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32042188'}, {'offsetInBeginSection': 327, 'offsetInEndSection': 509, 'text': 'Recently, ATAC-seq (assay for transposase-accessible chromatin using sequencing) has emerged as one of the most powerful approaches for genome-wide chromatin accessibility profiling.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30948010'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'Assay for transposase-accessible chromatin using sequencing data (ATAC-seq) is an efficient and precise method for revealing chromatin accessibility across the genome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33584814'}, {'offsetInBeginSection': 124, 'offsetInEndSection': 260, 'text': 'We previously developed a single-cell DNase-seq assay (scDNase-seq) to profile accessible chromatin in a limited number of single cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33693880'}, {'offsetInBeginSection': 688, 'offsetInEndSection': 770, 'text': 'DNase-seq and the more recent ATAC-seq are two assays that are gaining popularity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27008018'}, {'offsetInBeginSection': 510, 'offsetInEndSection': 691, 'text': 'This method assesses DNA accessibility using hyperactive Tn5 transposase, which simultaneously cuts DNA and inserts sequencing adaptors, preferentially in regions of open chromatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30948010'}, {'offsetInBeginSection': 178, 'offsetInEndSection': 426, 'text': 'For example, assay for transposase accessible chromatin sequencing (ATAC-seq) identifies nucleosome-depleted (open) chromatin, which harbors potentially active gene regulatory sequences; and bisulfite sequencing (BS-seq) quantifies DNA methylation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31160376'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 111, 'text': 'Characterization of chromatin accessibility with a transposome hypersensitive sites sequencing (THS-seq) assay.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846207'}, {'offsetInBeginSection': 343, 'offsetInEndSection': 471, 'text': 'We present a transposome hypersensitive sites sequencing assay for highly sensitive characterization of chromatin accessibility.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846207'}, {'offsetInBeginSection': 145, 'offsetInEndSection': 261, 'text': 'DNase I and Tn5 transposase assays require thousands to millions of fresh cells for comprehensive chromatin mapping.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846207'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'The assay for transposase-accessible chromatin using sequencing (ATAC-seq) provides a simple and scalable way to detect the unique chromatin landscape associated with a cell type and how it may be altered by perturbation or disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35478247'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Assay for Transposase-Accessible Chromatin using sequencing (ATAC-Seq) is a method to investigate the accessibility of chromatin in a genome-wide fashion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34382186'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 189, 'text': 'The assay for transposase-accessible chromatin using sequencing (ATAC-seq) has become the preferred method for mapping chromatin accessibility due to its time and input material efficiency.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32213349'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 200, 'text': 'Chromatin accessibility profiling assays such as ATAC-seq and DNase1-seq offer the opportunity to rapidly characterize the regulatory state of the genome at a single nucleotide resolution.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30064353'}, {'offsetInBeginSection': 186, 'offsetInEndSection': 414, 'text': \"Chromatin accessibility experiments such as DNaseI sequencing (DNase-seq) and Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) produce genome-wide data that include distinct 'footprint' patterns at binding sites.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27993786'}]\n\n\n                 'What are the most common assays to profile chromatin accessibility?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"ATAC-seq\", \"Assay for Transposase Accessible Chromatin sequencing\", \"DNase-seq\", \"FAIRE-seq\", \"MNase-seq\", \"Micrococcal nuclease\", \"MNase\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 352, 'offsetInEndSection': 651, 'text': \"We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich's ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n                 'What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"1.8 g/day\", \"9.0 g/day\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 1037, 'offsetInEndSection': 1129, 'text': 'The tools used to control pain in infants in the article included PIPP,NFCS,NIPS AND NPASS. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35410609'}, {'offsetInBeginSection': 98, 'offsetInEndSection': 226, 'text': 'The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS) are valid measures of pain. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35362716'}, {'offsetInBeginSection': 526, 'offsetInEndSection': 758, 'text': 'Fifteen bedside nurses trained to use the N-PASS and the NIPS prospectively completed 202 pain/agitation and sedation assessments from a convenience sample of 88 infants, including chronically ventilated, medically fragile infants. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35362716'}, {'offsetInBeginSection': 11, 'offsetInEndSection': 311, 'text': 'The present study evaluated the correlation of Neonatal Infant Pain Scale (NIPS) and Premature Infant Pain Profile-Revised (PIPP-R), with changes in cerebral oxygenation (\u0394crSO2; measured by near-infrared spectroscopy) in preterm infants during acute painful procedures (heel lance and venepuncture).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36271296'}, {'offsetInBeginSection': 427, 'offsetInEndSection': 523, 'text': 'A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291504'}, {'offsetInBeginSection': 79, 'offsetInEndSection': 379, 'text': 'The aim of this study was to assess the reliability, validity, and clinical utility of the Neonatal Facial Coding System (NFCS), Douleur Aigu\u00eb du Nouveau-n\u00e9 (DAN) scale, Neonatal Infant Pain Scale (NIPS), and Premature Infant Pain Profile (PIPP) in premature infants undergoing heel blood collection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32599608'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 462, 'text': \"BACKGROUND: Practical, valid and reliable pain measuring tools in neonates are required in clinical practice for effective pain management and prevention of the evaluator bias.METHODS: This prospective study was designed to cross-validate three pain scales: CRIES (cry, requires O(2), increased vital signs, expression, sleeplessness), CHIPPS (children's and infants' postoperative pain scale) and NIPS (neonatal infant pain scale) in terms of validity, reliabil\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16885171'}, {'offsetInBeginSection': 2163, 'offsetInEndSection': 2517, 'text': \"natal Infant Acute Pain Assessment Scale perform better in reliability. The Neonatal Pain, Agitation, and Sedation Scale appears to be a better choice for frontier nurses to assess procedural pain in ventilated neonates based on its good feasibility, utility and nurses' preference.RELEVANCE TO CLINICAL PRACTICE: Choosing a valid, reliable, feasible and\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29945293'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 542, 'text': 'OBJECTIVE: To temporally assess a painful stimulus in premature infants using 3 neonatal pain scales.METHODS: A total of 83 premature infants were observed during airway aspiration by 3 evaluators (E1, E2 and E3) using 3 pain assessment scales (Neonatal Facial Coding System - NFCS; Neonatal Infant Pain Scale - NIPS; and Premature Infant Pain Profile - PIPP) at 5 time points: T1 (before airway aspiration), T2 (during airway aspiration), T3 (1 minute after airway aspiration), T4 (3 minutes after airway aspiration), and T5 (5 minutes after', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32401971'}, {'offsetInBeginSection': 737, 'offsetInEndSection': 946, 'text': \"e frequently than Norwegian units. The most frequently used scales were different versions of Astrid Lindgren's Pain Scale (ALPS) in Sweden and Echelle Douleur Inconfort Noveau-Ne (EDIN), ALPS and Premature In\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29282767'}, {'offsetInBeginSection': 1766, 'offsetInEndSection': 2162, 'text': 'r than those of the Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by the Neonatal Infant Acute Pain Assessment Scale (23.5%) and the Premature Infant Pain Profile-Revised (20.6%).CONCLUSIONS: The three scales are all reliable and valid, but the Neonatal Pain, Agitation, and Sedation Scale and the Ne', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29945293'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 247, 'text': 'OBJECTIVE: This study evaluated neonatal pain scales during procedures commonly performed in a neonatal intensive care unit.DESIGN: Evaluated were the Neonatal Infant Pain Scale (NIPS), the Comfort scale, and a new scale known as the Scale for Use', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9535312'}, {'offsetInBeginSection': 288, 'offsetInEndSection': 517, 'text': 'uded in the study. Video recordings of infants during heel prick blood sampling were evaluated by two observers according to the Neonatal Infant Pain Scale (NIPS), the Neonatal Facial Coding System (NFCS), and the Douleur Aigu\u00eb d', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18446656'}, {'offsetInBeginSection': 616, 'offsetInEndSection': 832, 'text': 'Pain was assessed using indicators from three previously established scales (CRIES, the Premature Infant Pain Profile, and the Neonatal Infant Pain Scale), as well as the COVERS Scale, depending upon gestational age.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20976299'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': '[Measures for the assessment of pain in neonates as well as a comparison between the Bernese Pain Scale for Neonates (BPSN) with the Premature Infant Pain Profile (PIPP)].', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14747965'}, {'offsetInBeginSection': 427, 'offsetInEndSection': 522, 'text': 'A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291504'}, {'offsetInBeginSection': 1783, 'offsetInEndSection': 1933, 'text': 'he Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29945293'}]\n\n\n                 'What are the most common pain scales used to measure pain in neonates?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"PIPP\", \"Premature Infant Pain Profile-Revised\", \"NFCS\", \"Neonatal Facial Coding System\", \"NIPS\", \"Neonatal Infant Pain Scale\", \"NPASS\", \"Neonatal Pain, Agitation, and Sedation Scale\", \"N-PASS\", \"PIPP-R\", \"Premature Infant Pain Profile-Revised (PIPP-R)\", \"DAN\", \"Douleur Aigu\\u00eb du Nouveau-n\\u00e9\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35940183'}, {'offsetInBeginSection': 349, 'offsetInEndSection': 1031, 'text': 'METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35940183'}]\n\n\n                 'Which drugs were studied in the TRICOTEL study?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"atezolizumab\", \"vemurafenib\", \"cobimetinib\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 211, 'offsetInEndSection': 398, 'text': 'Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35562158'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 451, 'text': 'This chapter reviews the most common forms of congenital muscular dystrophies, including laminin \u03b1-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of \u03b1-dystroglycan.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23622361'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 290, 'text': 'OBJECTIVES: The collagen VI related muscular dystrophies (COL6-RD), Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are among the most common congenital muscular dystrophies and are characterized by distal joint laxity and a combination of distal and proximal joint c', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29244830'}, {'offsetInBeginSection': 521, 'offsetInEndSection': 887, 'text': 'g more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 630, 'offsetInEndSection': 871, 'text': 'In this review, we summarize the clinical features of two of the most common congenital muscular dystrophies, COL6-related dystrophies and LAMA2-related dystrophies, which are caused by mutations in muscle ECM and basement membrane proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29933045'}, {'offsetInBeginSection': 334, 'offsetInEndSection': 441, 'text': 'Mutations in LAMA2 cause the most common type of congenital muscular dystrophies, called LAMA2 MD or MDC1A.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29191403'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'Dystroglycanopathies are a clinically and genetically diverse group of recessively inherited conditions ranging from the most severe of the congenital muscular dystrophies, Walker-Warburg syndrome, to mild forms of adult-onset limb-girdle muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23288328'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'Congenital muscular dystrophy type 1A (MDC1A), the most common congenital muscular dystrophy in Western countries, is caused by recessive mutations in LAMA2, the gene encoding laminin alpha 2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34568901'}, {'offsetInBeginSection': 607, 'offsetInEndSection': 784, 'text': ' most common forms were those with \u03b1-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin \u03b12 deficiency (24.11%) and collagen VI deficiency (20.24%). Th', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25653289'}, {'offsetInBeginSection': 558, 'offsetInEndSection': 924, 'text': 'his article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and \u03b1-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31794464'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 217, 'text': \"Congenital LAMA2 related muscular dystrophy (LAMA2-RD), the most commonly recognized type of congenital muscular dystrophies, has been described in patients' cohorts from Europe and the UK but not from Middle-Eastern.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32444167'}, {'offsetInBeginSection': 386, 'offsetInEndSection': 536, 'text': 's and degeneration apparent at birth or in the first 6 months of life. LAMA2 MD is the most common congenital muscular dystrophy, affecting approximat', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31308722'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 227, 'text': 'Fukuyama congenital muscular dystrophy is one of the most common autosomal recessive disorders in the Japanese population, characterized by congenital muscular dystrophy in combination with cortical dysgenesis (micropolygyria).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10734260'}, {'offsetInBeginSection': 157, 'offsetInEndSection': 307, 'text': 's in Laminin a2. Turk J Pediatr 2017; 59: 338-341. Laminin \u03b12 related congenital muscular dystrophy is one of the most common congenital muscular dyst', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29376585'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 213, 'text': 'LAMA2-related congenital muscular dystrophy (MDC1A), the most commonly recognized type of congenital muscular dystrophies, is a severe neonatal onset muscle disease caused by recessive mutations in the LAMA2 gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36334577'}]\n\n\n                 'What are the most common congenital muscular dystrophies?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"dystroglycanopathies\", \"merosin-deficient CMD\", \"merosin-deficient congenital muscular dytrophy\", \"collagen VI-deficient CMD\", \"collagen VI-deficient congenital muscular dytrophy\", \"LMNA-related CMD\", \"LMNA-related congenital muscular dytrophy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 205, 'text': 'Nonlinear laser wave-mixing spectroscopy is demonstrated as a fast and sensitive detection method for heart-failure biomarkers, pro-atrial natriuretic peptide (proANP) and brain natriuretic peptide (BNP). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36152606'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 380, 'text': 'Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses, typically in the absence of elevated cardiac-filling pressures or clinical heart failure. Elevation of brain natriuretic peptide (BNP) or NT-proBNP is associated with worse outcomes among patients with Acute Respiratory Distress Syndrome (ARDS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33520785'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33002457'}, {'offsetInBeginSection': 272, 'offsetInEndSection': 508, 'text': 'Eight natriuretic peptides have been described so far: ANP, BNP, CNP, DNP, urodilatin, uroguanylin, osteocrin, musculin and three receptors: NPR-A, NPR-B and NPR-C thanks to which these hormones accomplish their physiological functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33130802'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34871602'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 242, 'text': 'Natriuretic peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) are cardiac and vascular peptides with vasodilatory, diuretic, natriuretic, anti-inflammatory, antifibrotic and antimitogenic actions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16548773'}, {'offsetInBeginSection': 135, 'offsetInEndSection': 411, 'text': 'There are four different groups NPs identified till date [atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide, a D-type natriuretic peptide (DNP)], each with its own characteristic functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22145138'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17965966'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'The natriuretic system consists of the atrial natriuretic peptide (ANP) and four other similar peptides including the wrongly named brain natriuretic peptide (BNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23776857'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 201, 'text': 'The natriuretic peptide family is comprised of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide - DNP and urodilatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19747125'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 200, 'text': 'Four major natriuretic peptides have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and Dendroaspis-type natriuretic peptide (DNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18703404'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 315, 'text': 'Atrial natriuretic peptides (ANPs) consist of a family of peptides (atrial natriuretic factor [ANF], long acting natriuretic peptide, vessel dilator, kaliuretic peptide, urodilatin, brain natriuretic peptide [BNP], and C type natriuretic peptide [CNP]) which are synthesized within the heart, except for urodilatin.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12189309'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 286, 'text': 'Since the discovery of the natriuretic effect of atrial natriuretic peptide (ANP), a family of other natriuretic peptides similar to ANP were isolated, including atriopeptin, vessel dilator, long-acting natriuretic peptide, urodilatin, and brain natriuretic peptide (BNP) to name a few.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11339846'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 364, 'text': 'The natriuretic peptide system is a complicated system comprising at least three endogenous peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) and three receptors [the atrial natriuretic peptide-A receptor (guanylyl cyclase A), the atrial natriuretic peptide-B receptor (guanylyl cyclase B) and the clearance receptor].', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8834155'}, {'offsetInBeginSection': 170, 'offsetInEndSection': 332, 'text': '126 amino acid atrial natriuretic peptide (ANP), 108 amino acid B-type natriuretic peptide (BNP) and 103 amino acid C-type natriuretic peptide (CNP) prohormones).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16487258'}, {'offsetInBeginSection': 336, 'offsetInEndSection': 707, 'text': \"The recent description of the C-type peptide CNP, the major brain-derived peptide, has suggested that original studies examining the endocrine actions of the natriuretic peptides using A-type (ANP) or B-type (BNP) isoforms might have underestimated some of the biopotency of the natriuretic peptides or even failed to detect the full spectrum of the family's bioactivity.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18407084'}, {'offsetInBeginSection': 274, 'offsetInEndSection': 496, 'text': 'The NP family includes atrial natriuretic peptide (ANP, 28AA), urodilatin (INN: Ularitide, 32 AA), B-type natriuretic peptide (BNP, 32AA), C-type natriuretic peptide (CNP, 22AA), and D-type natriuretic peptide (DNP, 38AA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19149542'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 171, 'text': 'Atrial cardiocytes in the heart of mammals produce in a regulated manner the polypeptide hormones atrial natriuretic factor (ANF, ANP) and brain natriuretic peptide (BNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16269246'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': 'Three types of natriuretic peptides (NP) have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15758553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Natriuretic hormones (NH) include three groups of compounds: the natriuretic peptides (ANP, BNP and CNP), the gastrointestinal peptides (guanylin and uroguanylin), and endogenous cardiac steroids.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25506340'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 195, 'text': 'The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29859763'}, {'offsetInBeginSection': 169, 'offsetInEndSection': 429, 'text': 'The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26961205'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Natriuretic peptides family consists of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), while receptors for these natriuretic peptides comprise at least three subtypes, i.e.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8392634'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Natriuretic peptide family consists of several hormones produced by cardiomyocyte, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22382054'}, {'offsetInBeginSection': 96, 'offsetInEndSection': 299, 'text': 'Four types of natriuretic peptides have been found thus far: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and Dendroaspis natriuretic peptide (DNP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12843686'}, {'offsetInBeginSection': 111, 'offsetInEndSection': 351, 'text': 'The natriuretic peptides - atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide - comprise a family of proteins that participate in the integrated control of intravascular volume and arterial blood pressure.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11476733'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 144, 'text': 'The natriuretic peptide family consists of three members: atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7496058'}, {'offsetInBeginSection': 128, 'offsetInEndSection': 293, 'text': 'They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12783635'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Cardiac natriuretic peptides (including ANP, BNP, CNP and urodilatin) constitute a family of peptide hormones and neurotransmitters, sharing similar chemical structure (characterized by a cysteine bridge) and biological function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16565701'}, {'offsetInBeginSection': 183, 'offsetInEndSection': 333, 'text': ' that activate receptor guanylate cyclases, namely, natriuretic peptide receptor (NPR)-A and NPR-B. Exposure of cells to atrial natriuretic peptide (A', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8967430'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 168, 'text': 'BACKGROUND: In mammals, the natriuretic system contains three natriuretic peptides, NPPA, NPPB and NPPC, that bind to three transmembrane receptors, NPR1, NPR2 and NPR3', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31771521'}]\n\n\n                 'Please list the natriuretic peptides.'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"B-type natriuretic peptide\", \"brain type natriuretic peptide\", \"NT-proBNP\", \"DNP\", \"CNP\", \"eurodilatin\", \"uroguanylin\", \"ANP\", \"osteocrin\", \"Musculin\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 355, 'text': 'Ubiquitination is a post-translational modification that generally directs proteins for degradation by the proteasome or by lysosomes. However, ubiquitination has been implicated in many other cellular processes, including transcriptional regulation, DNA repair, regulation of protein-protein interactions and association with ubiquitin-binding scaffolds.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21926471'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 349, 'text': 'Ubiquitin is best known for its function in targeting proteins for degradation by the proteasome. Recent studies have revealed several new functions of ubiquitin that are independent of proteasomal degradation. These functions include the novel signaling roles of ubiquitin in DNA repair and the activation of protein kinases such as IkappaB kinase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15196553'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 146, 'text': 'Ubiquitination ofendogenous proteins is one of the key regulatory steps that guides protein degradation through regulation of proteasome activity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20886764'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Ubiquitination-the covalent conjugation of ubiquitin (Ub) to other cellular proteins-regulates a wide range of cellular processes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16608998'}, {'offsetInBeginSection': 100, 'offsetInEndSection': 411, 'text': 'Ubiquitination is a specific process associated with several highly regulated biological outcomes including cell cycle progression, differentiation, antigen presentation, retrovirus assembly, apoptosis, signal transduction, transcriptional activation, biological clocks, receptor downregulation and endocytosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11182597'}, {'offsetInBeginSection': 263, 'offsetInEndSection': 532, 'text': 'Although targeting for proteasomal degradation is the best studied outcome of ubiquitylation, we now understand that modification of proteins with ubiquitin has numerous other cellular roles that alter protein function and that are unrelated to proteasomal degradation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18228479'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Ubiquitination is a post-translational modification that regulates most cellular pathways and processes, including degradation of proteins by the proteasome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26917723'}, {'offsetInBeginSection': 391, 'offsetInEndSection': 571, 'text': 'The most widely studied effect of ubiquitination of proteins is proteasome-mediated substrate degradation; however, ubiquitination can also alter protein localization and function.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33192571'}, {'offsetInBeginSection': 152, 'offsetInEndSection': 296, 'text': 'Ubiquitination is a highly selective post-translational modification that involves the covalent conjugation of ubiquitin to a substrate protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645583'}, {'offsetInBeginSection': 476, 'offsetInEndSection': 664, 'text': 'In addition to proteasomal degradation, ubiquitination regulates other cellular processes, such as transcription, translation, endocytosis, receptor activity, and subcellular localization.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645583'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 232, 'text': 'Ubiquitination is controlled by a series of E1, E2, and E3 enzymes that can ligate ubiquitin to cellular proteins and dictate the turnover of a substrate and the outcome of signalling events such as DNA damage repair and cell cycle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35327659'}, {'offsetInBeginSection': 510, 'offsetInEndSection': 781, 'text': 'Ubiquitination is the covalent link of target proteins with the small protein ubiquitin and serves as a signal to target protein degradation by the proteasome or to other outcomes such as endocytosis, degradation by the lysosome or specification of cellular localization.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22827778'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 255, 'text': 'The covalent attachment of ubiquitin molecules to target proteins is a posttranslational modification that is involved not only in signaling processes leading to protein degradation but also in those resulting in activation, proliferation, and cell death.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22375051'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 443, 'text': 'Two of the best characterized functions of protein ubiquitination are to mark proteins for degradation by cytosolic proteasome and to promote the internalization of certain plasma membrane proteins via the endocytotic pathway, followed by their degradation in the vacuole.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12896807'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 207, 'text': 'Ubiquitination is a post-translational modification that can dynamically alter the function, degradation and transport of a protein, as well as its interaction with other proteins, and activity of an enzyme.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31931110'}, {'offsetInBeginSection': 577, 'offsetInEndSection': 870, 'text': 'Ubiquitination, the covalent link of the small 76-amino acid protein ubiquitin to target proteins, serves as a signal for protein degradation by the proteasome or for other outcomes such as endocytosis, degradation by the lysosome or directing these proteins to specific cellular compartments.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22399444'}]\n\n\n                 'What are the outcomes of ubiquitination?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Protein degradation\", \"Degradation\", \"Degradation of proteins\", \"DNA repair\", \"Transcriptional regulation\", \"Regulation of protein-protein interactions\", \"Protein kinase activation\", \"Activation of protein kinases\", \"Apoptosis\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 228, 'offsetInEndSection': 335, 'text': \"To evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in Friedreich's ataxia patients\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}, {'offsetInBeginSection': 652, 'offsetInEndSection': 731, 'text': 'The primary endpoints were safety, tolerability, and pharmacokinetic analysis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29624723'}]\n\n\n                 'What were the primary endpoints of the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich's ataxia patients?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"safety\", \"tolerability\", \"pharmacokinetic analysis\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 178, 'text': 'Serpentine supravenous hyperpigmentation (SSH) is a unique type of chemotherapy-associated drug eruption, characterized by hyperpigmentation along the superficial venous network.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31168954'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'Serpentine supravenous hyperpigmentation (SSH) is a rare vasculo-cutaneous entity that has been associated with peripheral infusion of chemotherapy agents, in particular 5-FU1-3, but also seen with docetaxel4,5, fotemustine6, and vinorelbine7. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29951170'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'Serpentine supravenous hyperpigmentation is a peculiar cutaneous eruption that follows the path of vein after intravenous injection of the chemotherapeutic agent. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28878924'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'Serpentine erythematous or hyperpigmented streaks along the superficial venous network proximal to the site of injection may occur as a distinctive eruption after infusion of several chemotherapeutic agents. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22136872'}, {'offsetInBeginSection': 193, 'offsetInEndSection': 404, 'text': 'Serpentine supravenous hyperpigmentation was the term coined by Hrushesky to describe increased pigmentation of the skin immediately overlying the venous network used for intravenous infusion of 5-fluorouracil. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20134385'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 116, 'text': 'Two cases of serpentine supravenous hyperpigmentation developing in the area of fotemustine infusions are reported. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1559000'}, {'offsetInBeginSection': 695, 'offsetInEndSection': 913, 'text': 'The serpentine supravenous hyperpigmentation on the lower extremities was uniform in width and color, which contrasts with the darker discoloration near the site of infusion seen with PSSH associated with chemotherapy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23745227'}]\n\n\n                 'What causes Serpentine Supravenous Hyperpigmentation?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"5-fluorouracil\", \"docetaxel\", \"fotemustine\", \"vinorelbine\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 782, 'text': 'The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metabolism and evading immune destruction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21376230'}, {'offsetInBeginSection': 364, 'offsetInEndSection': 680, 'text': 'We define seven hallmarks of cancer: selective growth and proliferative advantage, altered stress response favoring overall survival, vascularization, invasion and metastasis, metabolic rewiring, an abetting microenvironment, and immune modulation, while highlighting some considerations for the future of the field.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28560055'}, {'offsetInBeginSection': 125, 'offsetInEndSection': 557, 'text': 'These distinctive and complementary capabilities, defined as the \"hallmarks of cancer,\" include the ability of tumor cells and their microenvironment to sustain proliferative signaling, evade growth suppressors, resist cell death, promote replicative immortality, induce angiogenesis, support invasion and metastasis, reprogram energy metabolism, induce genomic instability and inflammation, and trigger evasion of immune responses.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31873723'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'Human cancers share properties referred to as hallmarks, among which sustained proliferation, escape from apoptosis, and genomic instability are the most pervasive.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25621662'}, {'offsetInBeginSection': 423, 'offsetInEndSection': 606, 'text': 'Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21376230'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'The hallmarks of cancer described by Hanahan and Weinberg are properties that cancer cells must possess for successful transformation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23932019'}, {'offsetInBeginSection': 227, 'offsetInEndSection': 422, 'text': 'They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21376230'}, {'offsetInBeginSection': 1097, 'offsetInEndSection': 1459, 'text': 'The integrative concept embodied in the hallmarks of cancer is helping to distill this complexity into an increasingly logical science, and the provisional new dimensions presented in this perspective may add value to that endeavor, to more fully understand mechanisms of cancer development and malignant progression, and apply that knowledge to cancer medicine.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35022204'}, {'offsetInBeginSection': 1117, 'offsetInEndSection': 1528, 'text': 'Based on extensive study of the cancer research literature, we propose four novel hallmarks of cancer, namely, the ability of cells to regress from a specific specialized functional state, epigenetic changes that can affect gene expression, the role of microorganisms and neuronal signalling, to be included in the hallmark conceptualization along with evidence of various means to exploit them therapeutically.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33465324'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 180, 'text': 'The hallmarks of cancer conceptualization is a heuristic tool for distilling the vast complexity of cancer phenotypes and genotypes into a provisional set of underlying principles.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35022204'}, {'offsetInBeginSection': 324, 'offsetInEndSection': 561, 'text': 'The hallmarks of cancer include six biological processes, including proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, inducing angiogenesis, and activating invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36283507'}, {'offsetInBeginSection': 635, 'offsetInEndSection': 854, 'text': 'Attention is paid to the emerging hallmarks, deregulation of cellular energy metabolism and evasion of immune destruction, and enabling characteristics, genome instability and mutation and tumour-promoting inflammation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23263268'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 434, 'text': 'This progression has been suggested to depend on six essential characteristics identified as the \"hallmarks of cancer,\" which include: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15864800'}, {'offsetInBeginSection': 935, 'offsetInEndSection': 1364, 'text': 'The six classical hallmarks of cancer (i.e., limitless replication, self-provision of proliferative stimuli, insensitivity to antiproliferative signals, disabled apoptosis, sustained angiogenesis, invasiveness/metastatic potential), as well as other common features of tumors (i.e., avoidance of the immune response, enhanced anabolic metabolism, disabled autophagy) may directly or indirectly implicate deregulated mitochondria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19698742'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 425, 'text': 'Hanahan and Weinberg (2000, Cell 100: 57-70) listed \"hallmarks\" of cancer that must be considered in order to understand the underlying determinants of carcinogenesis: (a) self-sufficiency in growth signals; (b) insensitivity to growth-inhibitory (antigrowth) signals; (c) evasion of programmed cell death (apoptosis); (d) limitedless replicative potential; (e) sustained angiogenesis; and (f) tissue invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15650245'}, {'offsetInBeginSection': 202, 'offsetInEndSection': 385, 'text': 'These hallmarks include; unlimited proliferation, evading growth suppressors, resisting cell death, replicative immortality, inducing angiogenesis, initiating invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31119147'}, {'offsetInBeginSection': 231, 'offsetInEndSection': 430, 'text': 'Cancer hallmarks include sustained proliferation, evading growth suppressors, metastasis, replicative immortality, angiogenesis, resisting cell death, altered cellular energetics, and immune evasion.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29495398'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 329, 'text': 'According to Hanahan and Weinberg, cancer manifests as six essential physiologic hallmarks: (1) self-sufficiency in growth signals, (2) insensitivity to growth-inhibitory signals, (3) evasion of programmed cell death, (4) limitless replicative potential, (5) sustained angiogenesis, and (6) invasion and metastasis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27935336'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 170, 'text': 'Tumors arise through waves of genetic alterations and clonal expansion that allow tumor cells to acquire cancer hallmarks, such as genome instability and immune evasion. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32092639'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 178, 'text': 'The hallmarks of cancer provide a highly cited and well-used conceptual framework for describing the processes involved in cancer cell development and tumourigenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33823788'}]\n\n\n                 'What are the hallmarks of cancer?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Sustaining proliferative signaling\", \"Evading growth suppressors\", \"Resisting cell death\", \"Enabling replicative immortality\", \"Inducing angiogenesis\", \"Activating invasion and metastasis\", \"Reprogramming of energy metabolism\", \"Evading immune destruction\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 316, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is an inherited muscular disorder clinically characterized by slowly progressive weakness affecting humero-peroneal muscles, early joint contractures and cardiomyopathy with conduction defects. Autosomal dominant and recessive forms are caused by mutations in lamin A/C gene.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16550925'}, {'offsetInBeginSection': 516, 'offsetInEndSection': 591, 'text': 'X-linked recessive form of EDMD is caused by mutation in EMD (or STA) gene ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16550925'}, {'offsetInBeginSection': 162, 'offsetInEndSection': 353, 'text': 'The LINC components emerin, lamin A/C, SUN1, SUN2, nesprin-1 and nesprin-2 interact with each other at the NE and also with other binding partners including actin filaments and B-type lamins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 473, 'offsetInEndSection': 590, 'text': 'Emerin was the first LINC component associated with a human disease, namely EDMD (Emery-Dreifuss muscular dystrophy).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 591, 'offsetInEndSection': 742, 'text': 'Later on, other components of the LINC complex, such as lamins A/C and small isoforms of nesprin-1 and nesprin-2, were found to be associated with EDMD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 814, 'offsetInEndSection': 973, 'text': 'Only approximately 46% of the EDMD patients can be linked to genes of LINC and non-LINC components, pointing to further genes involved in the pathology of EDMD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 1030, 'offsetInEndSection': 1215, 'text': ' Recently, screening of binding partners of LINC components as candidates identified LUMA (TMEM43), encoding a binding partner of emerin and lamins, as a gene involved in atypical EDMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 1303, 'offsetInEndSection': 1354, 'text': ' EDMD-causing mutations in STA/EMD (encoding emerin', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22103509'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 564, 'text': 'Emery-Dreifuss muscular dystrophy (EDMD) is a rare muscular dystrophy, but is particularly important to diagnose due to frequent life-threatening cardiac complications. EDMD classically presents with muscle weakness, early contractures, cardiac conduction abnormalities and cardiomyopathy, although the presence and severity of these manifestations vary by subtype and individual. Associated genes include EMD, LMNA, SYNE1, SYNE2, FHL1, TMEM43, SUN1, SUN2, and TTN, encoding emerin, lamin A/C, nesprin-1, nesprin-2, FHL1, LUMA, SUN1, SUN2, and titin, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31840275'}]\n\n\n                 'Which genes are related to Emery-Dreifuss Muscular Dystrophy (EDMD)?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"EMD gene\", \"STA gene\", \"emerin gene\", \"lamin A/C gene\", \"LMNA\", \"SUN1\", \"SUN2\", \"nesprin-1 gene\", \"SYNE1\", \"nesprin-2 gene\", \"SYNE2\", \"LUMA (TMEM43)\", \"FHL1\", \"titin gene\", \"TTN\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 224, 'offsetInEndSection': 587, 'text': 'new firefly bioluminescence substrates, and further evaluated their activities in vitro and in vivo. It is worth noting that the maximum biological emission wavelength of novel luciferin analogue AL3 ((S,E)-2-(6-hydroxy-5-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) is 100 nm red-shifted compared with D-luciferin, ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551298'}, {'offsetInBeginSection': 610, 'offsetInEndSection': 711, 'text': 'AL4 ((S,E)-2-(5-(2-cyanovinyl)-6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551298'}, {'offsetInBeginSection': 733, 'offsetInEndSection': 919, 'text': 'The new substrate AL2 ((S,E)-2-(6-hydroxy-7-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid) showed better bioluminescence performance in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551298'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 243, 'text': 'The interaction of luciferases from two types of luminous bacteria, Photobacterium leiognathi and Vibrio harveyi, with their substrates [the photorecovered FMNH2 and long-chain aldehydes--decanal (C10), dodecanal (C12) and tetradecanal (C14)] ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11512142'}, {'offsetInBeginSection': 593, 'offsetInEndSection': 686, 'text': 'Following coadministration of two luciferase substrates, native coelenterazine and luciferin,', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17994900'}, {'offsetInBeginSection': 377, 'offsetInEndSection': 597, 'text': 'Comparisons of experimental data with predictions based upon the three inhibitory models show that product inhibition during luciferase luminescence is noncompetitive with respect to both luciferin and ATP as substrates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/836795'}, {'offsetInBeginSection': 140, 'offsetInEndSection': 429, 'text': 'An alternative luciferase (Luc) substrate cyclic luciferin (Cycluc) was recently advanced for BLI applications as providing a stronger, more stable signal at significantly lower doses than the classical substrate D-luciferin (D-Luc) increasing sensitivity of Luc detection 10 to 100 times.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30979501'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 43, 'text': 'ATP is one of the substrates of luciferase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15165512'}, {'offsetInBeginSection': 286, 'offsetInEndSection': 504, 'text': 'D-luciferin, a natural substrate of firefly luciferase, has been reported to have limited brain distribution, possibly due to the efflux transporter, breast cancer resistance protein (Bcrp), at the blood-brain barrier.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34887255'}, {'offsetInBeginSection': 204, 'offsetInEndSection': 324, 'text': '4-Methyl-D-luciferin is a substrate of Photinus pyralis luciferase, and it causes light emission in luminometric assays.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2230665'}, {'offsetInBeginSection': 1501, 'offsetInEndSection': 1659, 'text': 'This study examined the pharmacokinetics, brain distribution, and the role of active efflux transporters on the luciferase substrates D-luciferin and CycLuc1.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34887255'}, {'offsetInBeginSection': 102, 'offsetInEndSection': 337, 'text': 'Antares, a fusion of the luciferase NanoLuc to the orange fluorescent protein CyOFP, has emerged as a bright bioluminescent reporter with orthogonal substrate specificity to firefly luciferase (FLuc) and its derivatives such as AkaLuc.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32661427'}, {'offsetInBeginSection': 243, 'offsetInEndSection': 377, 'text': \"Here we report cost-effective and efficient syntheses of d-luciferin and 6'-aminoluciferin, two widely used bioluminescent substrates.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25525906'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 87, 'text': 'd-Luciferin is a popular bioluminescent substrate of luciferase in the presence of ATP.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31764924'}, {'offsetInBeginSection': 197, 'offsetInEndSection': 347, 'text': 'cusing on the tissue distribution of two luciferase substrates, D-luciferin and CycLuc1. D-luciferin, a natural substrate of firefly luciferase, has b', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34887255'}, {'offsetInBeginSection': 699, 'offsetInEndSection': 849, 'text': ' non-competitive manner with respect to the luciferase substrates D-luciferin and ATP. By contrast, the compound has no effect on Renilla and Gaussia ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22789175'}, {'offsetInBeginSection': 700, 'offsetInEndSection': 850, 'text': 'non-competitive manner with respect to the luciferase substrates D-luciferin and ATP. By contrast, the compound has no effect on Renilla and Gaussia l', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22789175'}]\n\n\n                 'List the luciferase substrates'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"luciferin\", \"coelenterazine (CTZ\", \"AL3 ((S,E)-2-(6-hydroxy-5-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid)\", \"AL4 ((S,E)-2-(5-(2-cyanovinyl)-6-hydroxybenzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid)\", \"AL2 ((S,E)-2-(6-hydroxy-7-(3-methoxy-3-oxoprop-1-en-1-yl)benzo[d]thiazol-2-yl)-4,5-dihydrothiazole-4-carboxylic acid)\", \"FMNH2\", \"Decanal\", \"long chain aldehydes\", \"dodecanal\", \"tetradecanal\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), necrotizing myopathy (NM), antisynthetase syndrome (ASS) and overlap myositis (OM), in short myositis, are rare diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35394612'}, {'offsetInBeginSection': 135, 'offsetInEndSection': 407, 'text': 'This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767470'}, {'offsetInBeginSection': 307, 'offsetInEndSection': 650, 'text': 'The search strategy from the 2021 Cochrane Physical Activity review in neuromuscular disease was used, and we selected articles that included people with IIM, including Dermatomyositis (DM), Inclusion Body Myositis (IBM), Immune Mediated Necrotising Myopathy (IMNM) [also known as necrotizing autoimmune myopathy (NAM)], and Polymyositis (PM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35927155'}, {'offsetInBeginSection': 172, 'offsetInEndSection': 438, 'text': 'We present evidence based on recently emerged clinical, histologic, immunopathologic, demographic and therapeutic observations that these myopathies comprise three major and distinct groups: polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1423335'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 167, 'text': 'The inflammatory myopathies, including dermatomyositis, inclusion body myositis, and polymyositis, are poorly understood autoimmune diseases affecting skeletal muscle.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18351525'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'There are five major types of idiopathic inflammatory myopathies: dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), autoimmune necrotizing myopathy (AINM) and inflammatory myopathies associated with connective tissue diseases (overlap myositis).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19282137'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 267, 'text': 'Idiopathic inflammatory myopathy (IIM) is the umbrella term including dermatomyositis (DM), polymyositis (PM), overlap myositis (OM), sporadic inclusion body myositis (IBM) and necrotising autoimmune myopathy (NAM), also known as immune-mediated necrotising myopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155760'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 307, 'text': 'Idiopathic inflammatory myopathies (IIMs), except for sporadic inclusion body myositis (sIBM), present with subacute symmetrical weakness of the limb girdle muscles, an elevated serum creatine kinase activity, and inflammatory cells in the muscle biopsy (necrotizing autoimmune myopathy being an exception).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24365315'}, {'offsetInBeginSection': 428, 'offsetInEndSection': 658, 'text': 'Five main types of inflammatory myopathies are now widely recognised: dermatomyositis, immune-mediated necrotising myopathy, sporadic inclusion-body myositis, overlap myositis (including antisynthetase syndrome), and polymyositis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30129477'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 140, 'text': 'PURPOSE OF REVIEW: The inflammatory myopathies include polymyositis, dermatomyositis, necrotizing autoimmune myopathy (NAM), and inclusion b', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21799409'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 196, 'text': 'Idiopathic inflammatory myopathies (IM), including dermatomyositis (DM) and polymyositis (PM), are a group of systemic rheumatologic diseases of unknown etiology characterized by chronic myositis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16769661'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 287, 'text': 'Idiopathic inflammatory myopathies are a group of heterogeneous striated muscle acquired autoimmune diseases, characterized by progressive symmetrical muscle weakness, elevated serum levels of muscle enzymes, electromyographic abnormalities and inflammatory infiltrates on muscle biopsy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21794659'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 270, 'text': 'Inflammatory myopathies are a group of immune-mediated muscle disorders comprising dermatomyositis; polymyositis; overlap myositis, including antisynthetase syndromes and nonspecific myositis, immune-mediated necrotizing myopathies, and sporadic inclusion body myositis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32703475'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 164, 'text': 'The idiopathic inflammatory myopathies are a group of rare disorders including polymyositis (PM), dermatomyositis (DM), and autoimmune necrotizing myopathies (NMs).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23117947'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 244, 'text': 'OBJECTIVE: The molecular basis of inflammatory myopathies such as dermatomyositis (DM), polymyositis, and inclusion body myositis, which share the characteristics of chronic muscle inflammation and skeletal muscle wasting, are poorly understood', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24757153'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'The idiopathic inflammatory myopathies include polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22870499'}, {'offsetInBeginSection': 515, 'offsetInEndSection': 665, 'text': ' the common inflammatory myopathies, i.e. dermatomyositis, polymyositis, and sporadic inclusion body myositis, and to describe the specific spectrum o', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33554607'}]\n\n\n                 'Which are the known inflammatory myopathies?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"polymyositis\", \"PM\", \"dermatomyositis\", \"DM\", \"inclusion body myositis\", \"IBM\", \"necrotizing myopathy\", \"NM\", \"antisynthetase syndrome\", \"ASS\", \"overlap myositis\", \"OM\", \"myositis\", \"immune-mediated necrotizing myopathy\", \"IMNM\", \"necrotizing autoimmune myopathy\", \"NAM\", \"sporadic inclusion body myositis\", \"sIBM\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 143, 'offsetInEndSection': 371, 'text': 'It is a serious threat to prehospital patients and especially injured patients, since it can induce a vicious cycle of the synergistic effects of hypothermia, acidosis and coagulopathy; referred to as the trauma triad of death. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29162267'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 67, 'text': 'The trauma triad of death: hypothermia, acidosis, and coagulopathy.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10347389'}, {'offsetInBeginSection': 665, 'offsetInEndSection': 854, 'text': 'The \"new\" golden hour may well be the time in the operating room before the patient reaches the physiologic limit, defined as the onset of the triad: hypothermia, acidosis and coagulopathy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10347389'}]\n\n\n                 'What are features of the The Trauma Triad of Death?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"hypothermia\", \"acidosis\", \"coagulopathy\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 437, 'offsetInEndSection': 636, 'text': 'Epigenetic modifications may constitute changes in DNA methylation, histone modifications (methylation, acetylation etc), and changes in non-coding RNA, leading to an altered gene expression profile.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583646'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 162, 'text': 'Epigenetic modifications viz. DNA methylation, histone modifications, and RNA-based alterations play a crucial role in the development of cardiovascular diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34870779'}, {'offsetInBeginSection': 275, 'offsetInEndSection': 400, 'text': 'Major epigenetic modifications are DNA methylation, histone modification, chromatin remodeling as well as the noncoding RNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33605616'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 479, 'text': 'Eukaryotic gene expression is regulated not only by genomic enhancers and promoters, but also by covalent modifications added to both chromatin and RNAs. Whereas cellular gene expression may be either enhanced or inhibited by specific epigenetic modifications deposited on histones (in particular, histone H3), these epigenetic modifications can also repress viral gene expression, potentially functioning as a potent antiviral innate immune response in DNA virus-infected cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32533130'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 286, 'text': 'Examples of epigenetic control are DNA methylation, histone deacetylation and mi-RNA expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28259291'}, {'offsetInBeginSection': 558, 'offsetInEndSection': 701, 'text': 'These modifications are dubbed as \"epigenetic modifications\" and include, among others, histone modifications, DNA methylation, and small RNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20920747'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Epigenetic changes are defined as inherited modifications that are not present in DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28259291'}, {'offsetInBeginSection': 171, 'offsetInEndSection': 293, 'text': 'Examples of such modifications include DNA methylation, histone modifications, noncoding RNAs, and chromatin architecture.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23935066'}, {'offsetInBeginSection': 118, 'offsetInEndSection': 312, 'text': 'DNA methylation and histone modifications, for example, are capable of spatial and temporal regulation of expression-with several studies demonstrating that these epigenetic marks are heritable.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26074949'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 166, 'text': 'DNA methylation and histone modifications such as methylation, acetylation, and phosphorylation, are two types of epigenetic modifications that alter gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30679030'}, {'offsetInBeginSection': 456, 'offsetInEndSection': 631, 'text': 'In the present review we discuss three prominent epigenetic modifications, DNA methylation, histone methylation/acetylation, and the effects of chromatin remodeling complexes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35735917'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'In the current era of epigenetics research, we have observed many examples of epigenetic modifications, like histone modification and DNA methylation, in various fatal diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29992310'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Epigenetic modifications, such as DNA methylation and histone modification, result in heritable changes in gene expression without changing the DNA sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30984620'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 203, 'text': 'DNA methylation has been characterized as the representative example of epigenetic modifications and implicated in numerous biological processes, such as genomic imprinting and X chromosome inactivation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31989558'}, {'offsetInBeginSection': 673, 'offsetInEndSection': 814, 'text': 'Methylation and histone acetylation are two of the most well-studied examples of the epigenetic modifications that occur on histone proteins.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34421981'}, {'offsetInBeginSection': 115, 'offsetInEndSection': 219, 'text': 'One example of epigenetic factors is DNA methylation, which prevents certain genes from being expressed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24743128'}, {'offsetInBeginSection': 815, 'offsetInEndSection': 930, 'text': 'DNA methylation is the type of epigenetic modification that alters gene expression without modifying gene sequence.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34421981'}, {'offsetInBeginSection': 300, 'offsetInEndSection': 490, 'text': 'Epigenetic modifications are chromosome-bound, heritable changes to the genome that do not affect the DNA sequence, and can include DNA methylation, histone modification, and RNA processing.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28069135'}, {'offsetInBeginSection': 224, 'offsetInEndSection': 386, 'text': 'Epigenetic alterations such as DNA methylation and histone modification are essential for chromatin remodeling and regulation of gene expression including miRNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23056006'}, {'offsetInBeginSection': 346, 'offsetInEndSection': 476, 'text': 'This review summarises the main epigenetic modifications in mammals, especially DNA methylation, histone modifications, and ncRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35052371'}]\n\n\n                 'What are some examples of epigenetic modifications?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"DNA methylation\", \"Histone modifications\", \"Histone acetylation\", \"Histone methylation\", \"Chromatin remodeling\", \"Non-coding RNA\", \"Noncoding RNA\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 212, 'text': \"Friedreich's ataxia is classically considered a disease with onset in the first or second decade. However, late-onset (age of onset 25-39 years) and very-late-onset (age of onset >40 years) forms do occur rarely.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31467149'}, {'offsetInBeginSection': 1696, 'offsetInEndSection': 1902, 'text': \"and Friedreich's ataxia is heterogeneous. Late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia appear to belong to the same clinical and molecular continuum and should be considered togeth\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 57, 'offsetInEndSection': 218, 'text': \" age of 25. Rare variants have been described, such as late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia, occurring after 25 and 40 years, r\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 219, 'offsetInEndSection': 1021, 'text': \"spectively. We describe the clinical, functional, and molecular findings from a large series of late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia and compare them with typical-onset Friedreich's ataxia.METHODS: Phenotypic and genotypic comparison of 44 late-onset Friedreich's ataxia, 30 very late-onset Friedreich's ataxia, and 180 typical Friedreich's ataxia was undertaken.RESULTS: Delayed-onset Friedreich's ataxia (late-onset Friedreich's ataxia and very-late-onset Friedreich's ataxia) had less frequently dysarthria, abolished tendon reflexes, extensor plantar reflexes, weakness, amyotrophy, ganglionopathy, cerebellar atrophy, scoliosis, and cardiomyopathy than typical-onset Friedreich's ataxia, along with less severe functional disability and shorter GAA expansion on t\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26388117'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 137, 'text': \"Very late-onset Friedreich's ataxia (VLOFA) is characterized by symptomatic onset after 40 years of age and, usually, a benign phenotype.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16092110'}, {'offsetInBeginSection': 871, 'offsetInEndSection': 1101, 'text': \"ing Scale and EQ-5D. The Friedreich's ataxia cohort was subdivided into three groups: early disease onset (\u226414 years), intermediate onset (15-24 years), and late onset (\u226525 years), which were compared for clinical characteristics \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25566998'}, {'offsetInBeginSection': 893, 'offsetInEndSection': 1123, 'text': \"he Friedreich's ataxia cohort was subdivided into three groups: early disease onset (\u226414 years), intermediate onset (15-24 years), and late onset (\u226525 years), which were compared for clinical characteristics and outcome measures. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25566998'}]\n\n\n                 'Which are the types of Friedreich's Ataxia based on onset age?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Friedreich's ataxia\", \"early-onset FA\", \"early-onset Friedreich's ataxia\", \"late-onset Friedreich's ataxia\", \"late-onset FA\", \"very-late-onset Friedreich's ataxia\", \"very-late-onset FA\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 301, 'text': 'Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35671774'}, {'offsetInBeginSection': 4240, 'offsetInEndSection': 4449, 'text': 'INTERPRETATION: Updated FAKTION data showed that capivasertib addition to fulvestrant extends the survival of participants with aromatase inhibitor-resistant ER-positive, HER2-negative advanced breast cancer. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35671774'}, {'offsetInBeginSection': 866, 'offsetInEndSection': 955, 'text': 'Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36110891'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 221, 'text': 'Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32035020'}, {'offsetInBeginSection': 130, 'offsetInEndSection': 318, 'text': 'The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32035020'}]\n\n\n                 'Which drugs were tested in the FAKTION trial?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"capivasertib\", \"fulvestrant\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 260, 'text': 'RNA splicing is a critical step in the maturation of precursor mRNA (pre-mRNA) by removing introns and exons. The combination of inclusion and exclusion of introns and exons in pre-mRNA can generate vast diversity in mature mRNA from a limited number of genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33923658'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 285, 'text': \"Transport of messenger RNA (mRNA) from the nucleus to the cytoplasm is an essential step of eukaryotic gene expression. In the cell nucleus, a precursor mRNA undergoes a series of processing steps, including capping at the 5' ends, splicing and cleavage/polyadenylation at the 3' ends.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25836925'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 249, 'text': \"Messenger RNA precursors (pre-mRNAs) are produced as the nascent transcripts of RNA polymerase II (Pol II) in eukaryotes and must undergo extensive maturational processing, including 5'-end capping, splicing, and 3'-end cleavage and polyadenylation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24617759'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 250, 'text': 'The cellular transformation of a precursor mRNA (pre-mRNA) into its mature or functional form proceeds by way of a splicing reaction, in which the exons are ligated to form the mature linear RNA and the introns are excised as branched or lariat RNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14576302'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 156, 'text': 'In eukaryotes, pre-messenger RNA (pre-mRNA) cleavage and polyadenylation is one of the necessary processing steps that produce a mature and functional mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25487206'}, {'offsetInBeginSection': 120, 'offsetInEndSection': 285, 'text': \"In the cell nucleus, a precursor mRNA undergoes a series of processing steps, including capping at the 5' ends, splicing and cleavage/polyadenylation at the 3' ends.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25836925'}, {'offsetInBeginSection': 156, 'offsetInEndSection': 372, 'text': \"The three most prevalent processing steps are the capping reaction at the 5'-end, the removal of intervening sequences by splicing, and the formation of poly (A)-tails at the 3'-end of the message by polyadenylation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21823231'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Precursor mRNA (pre-mRNA) splicing is a critical step in gene expression that results in the removal of intronic sequences from immature mRNA, leading to the production of mature mRNA that can be translated into protein.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25761502'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 103, 'text': \"Spliceosome and 3'-end processing complexes are necessary for the precursor mRNA (pre-mRNA) maturation.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27350684'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 228, 'text': 'Precursor messenger RNA (pre-mRNA) splicing is a fundamental step in eukaryotic gene expression that systematically removes non-coding regions (introns) and ligates coding regions (exons) into a continuous message (mature mRNA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34016162'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 109, 'text': 'RNA splicing is a critical step in the maturation of precursor mRNA (pre-mRNA) by removing introns and exons.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33923658'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 246, 'text': 'In trypanosomatid parasites, spliced leader (SL) trans splicing is an essential nuclear mRNA maturation step which caps mRNAs posttranscriptionally and, in conjunction with polyadenylation, resolves individual mRNAs from polycistronic precursors.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19429779'}, {'offsetInBeginSection': 289, 'offsetInEndSection': 459, 'text': 'The process of pre-mRNA cleavage and polyadenylation, and its relationship with RNA splicing and translation, have been extensively studied due to its importance in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25487206'}, {'offsetInBeginSection': 157, 'offsetInEndSection': 288, 'text': 'Regulation on pre-mRNA cleavage and polyadenylation affects other processes such as mRNA translocation, stability, and translation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25487206'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': \"The 3' ends of most eukaryotic messenger RNAs must undergo a maturation step that includes an endonuc-leolytic cleavage followed by addition of a polyadenylate tail.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25081038'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 106, 'text': 'mRNA polyadenylation and pre-mRNA splicing are two essential steps for the maturation of most human mRNAs.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17210931'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 157, 'text': 'Pre-mRNA (precursor mRNA) splicing is a key step in cellular gene expression where introns are excised and exons are ligated together to produce mature mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25110027'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 185, 'text': 'The process of removing intronic sequences from a precursor to messenger RNA (pre-mRNA) to yield a mature mRNA transcript via splicing is an integral step in eukaryotic gene expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27198613'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 257, 'text': 'Eukaryotic mRNA synthesis is a complex biochemical process requiring transcription of a DNA template into a precursor RNA by the multi-subunit enzyme RNA polymerase II and co-transcriptional capping and splicing of the precursor RNA to form the mature mRNA.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31132066'}, {'offsetInBeginSection': 134, 'offsetInEndSection': 273, 'text': 'With this step, a pre-messenger RNA is processed and polyadenylated, giving rise to a mature mRNA bearing the characteristic poly(A) tract.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18630752'}]\n\n\n                 'What are the necessary steps for the transition from a precursor mRNA to a mature\nmRNA?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Splicing\", \"RNA splicing\", \"pre-mRNA splicing\", \"Capping\", \"5'-end capping\", \"Capping at the 5' ends\", \"5' capping\", \"Polyadenylation\", \"3'-end cleavage and polyadenylation\", \"Cleavage/polyadenylation at the 3' ends\", \"3' polyadenylation\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 324, 'offsetInEndSection': 377, 'text': 'SMA with a clinical diagnosis of SMA types\\xa01, 2, or 3', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35284988'}, {'offsetInBeginSection': 591, 'offsetInEndSection': 751, 'text': ' In phase\\xa02/3 clinical trials, risdiplam significantly improved motor function in infants with SMA type\\xa01 and in patients aged 2-25\\xa0years with SMA types 2 or 3.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35284988'}, {'offsetInBeginSection': 190, 'offsetInEndSection': 265, 'text': 'Adulthood-onset SMA (SMA type 4) is rare, with few isolated cases reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090613'}, {'offsetInBeginSection': 643, 'offsetInEndSection': 739, 'text': 'Twenty patients with SMA type 4 were identified in a Brazilian cohort of 227 patients with SMA. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090613'}, {'offsetInBeginSection': 1675, 'offsetInEndSection': 1823, 'text': 'This study represents the largest cohort of patients with SMA type 4 and provides functional, genetic, radiological and neurophysiological features ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090613'}, {'offsetInBeginSection': 295, 'offsetInEndSection': 347, 'text': 'Adolescent and adult patients with SMA types 3 and 4', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35466947'}, {'offsetInBeginSection': 1632, 'offsetInEndSection': 1900, 'text': 'We found no evidence for the contribution of motor unit and capillary recruitment capacity of the upper arm muscles in adolescent and adult patients with SMA types 3 and 4 as primary limiting factors to premature fatigue during execution of a maximal arm-cycling task.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35466947'}, {'offsetInBeginSection': 262, 'offsetInEndSection': 350, 'text': 'We report a long-term follow-up in adolescent and adult patients with SMA types 1 and 2.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36335004'}, {'offsetInBeginSection': 359, 'offsetInEndSection': 463, 'text': 'Nusinersen-treated patients with SMA types 1 and 2 between 2017 and 2022 were retrospectively reviewed. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36335004'}, {'offsetInBeginSection': 922, 'offsetInEndSection': 1068, 'text': 'Seven patients with SMA (type 1, 1; type 2, 6) with a median age of 23 (range, 12-40)years were treated with nusinersen for 3.55 (1.78-4.53)years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36335004'}, {'offsetInBeginSection': 778, 'offsetInEndSection': 1010, 'text': 'On October 1st, 666 patients have been enrolled (357 children and 309 adults) by 44 out of 51 open centers of the national network (FILNEMUS) with: 150 type 1 (22%); 278 type 2 (42%), 232 type\\xa03 (35%) and 4 type 4 (1%) respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34878390'}, {'offsetInBeginSection': 122, 'offsetInEndSection': 396, 'text': 'The identification of the underlying gene defects for familial ALS, spinal muscular atrophy (SMA), and spinal muscular atrophy with respiratory distress (SMARD) has pointed to distinct pathophysiological mechanisms that are responsible for the various forms of the disease. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14704958'}, {'offsetInBeginSection': 1046, 'offsetInEndSection': 1149, 'text': 'Interestingly, UBA1 mutations can also cause infantile-onset X-linked spinal muscular atrophy (XL-SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 1150, 'offsetInEndSection': 1333, 'text': \"The mutation identified here and the XL-SMA causative mutations were shown to affect amino acids positioned in the vicinity of UBA1's ATP binding site and to cause structural changes.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 1515, 'offsetInEndSection': 1589, 'text': 'The contribution of this same gene to the etiology of XL-SMA is discussed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35996994'}, {'offsetInBeginSection': 525, 'offsetInEndSection': 791, 'text': 'Type I spinal muscular atrophy has been subdivided into 3 groups: - type IA, the clinical signs of which set in between birth and 15 days of life with sudden severe motor impairment, sucking-swallowing disorders attesting to bulbar involvement, respiratory distress.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33357591'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 310, 'text': 'The childhood form of the spinal muscular atrophy (SMA) is classically subdivided into three groups on the basis of a combination of age of onset, milestones of development and age of survival: acute Werdning-Hoffmann (type I), intermediate Werdnig-Hoffmann (type II) and Kugelberg-Welander disease (type III).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1389561'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 225, 'text': 'Spinal muscular atrophy type 3 (SMA3), also called Kugelberg-Welander SMA, typically presents with muscle fatigue, slowly progressive weakness and atrophy of lower limbs once they have already acquired independent ambulation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33357593'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Spinal muscular atrophy, X-linked 2 (SMAX2) is a rare type of spinal muscular atrophy characterized by muscle weakness, hypotonia, areflexia, myopathic face, tongue fibrillations, contractures, bone fractures, and cryptorchidism.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35707597'}, {'offsetInBeginSection': 185, 'offsetInEndSection': 315, 'text': 'SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16865356'}, {'offsetInBeginSection': 68, 'offsetInEndSection': 218, 'text': 'ring seated upper limb tasks in patients with spinal muscular atrophy types 2 and 3.DESIGN: Seventeen persons with spinal muscular atrophy and 15 heal', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31274514'}, {'offsetInBeginSection': 133, 'offsetInEndSection': 283, 'text': 'tional ability in children with non-ambulant spinal muscular atrophy types 2 and 3 in a longitudinal multi-center clinical trial. This study assessed ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16750368'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 208, 'text': 'BACKGROUND & AIMS: Different neuromuscular functional domains in types I and II Spinal Muscular Atrophy (SMAI and SMAII) could lead to differences in body composition (BC) and resting energy expenditure (REE)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27890489'}]\n\n\n                 'What are the types of Spinal Muscular Atrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"SMA type 1\", \"Spinal Muscular Atrophy type 1\", \"SMA 1\", \"SMA type 2\", \"Spinal Muscular Atrophy type 2\", \"SMA 2\", \"SMA type 3\", \"Spinal Muscular Atrophy type 3\", \"SMA 3\", \"SMA type 4\", \"Spinal Muscular Atrophy type 4\", \"SMA 4\", \"spinal muscular atrophy with respiratory distress\", \"SMARD\", \"X-linked Spinal Muscular Atrophy\", \"XL-SMA\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 175, 'offsetInEndSection': 335, 'text': 'Most commonly affecting males between 50 and 70 years of age, Clinically, the Mackler triad is vomiting, severe chest pain, and subcutaneous cervical emphysema.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34932533'}]\n\n\n                 'What are features of the Mackler\u2019s Triad?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"vomiting\", \"severe chest pain\", \"subcutaneous cervical emphysema\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 264, 'text': 'Motor neurons (MNs) are specialized neurons responsible for muscle contraction that specifically degenerate in motor neuron diseases (MNDs), such as amyotrophic lateral sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA), and spinal muscular atrophy (SMA). ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34603008'}, {'offsetInBeginSection': 449, 'offsetInEndSection': 612, 'text': 'Spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), hereditary spastic paraplegia (HSP), and amyotrophic lateral sclerosis (ALS) are all MNDs', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35511862'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 229, 'text': 'Amyotrophic Lateral Sclerosis (ALS), Spinal Bulbar Muscular Atrophy (SBMA), and Spinal Muscular Atrophy (SMA) are motor neuron diseases (MNDs) characterised by progressive motor neuron degeneration, weakness and muscular atrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36143200'}, {'offsetInBeginSection': 136, 'offsetInEndSection': 356, 'text': 'The most common MND are amyotrophic lateral sclerosis (ALS), proximal spinal muscular atrophy (SMA) and various forms of hereditary and sporadic lower motor neuron syndromes including hereditary motor neuropathies (HMN).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21626001'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 197, 'text': 'Two motor neuron diseases, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), are caused by distinct genes involved in RNA metabolism, TDP-43 and FUS/TLS, and SMN, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23255347'}, {'offsetInBeginSection': 147, 'offsetInEndSection': 302, 'text': 'Similarly other motor neuron diseases such as the spinal muscular atrophies (SMA) and the motor neuropathies (MN) were grouped following clinical criteria.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12710507'}, {'offsetInBeginSection': 499, 'offsetInEndSection': 685, 'text': 'There are several types of motor neuron disease: amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP), progressive muscular atrophy (PMA), primary lateral sclerosis (PLS).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32671738'}, {'offsetInBeginSection': 200, 'offsetInEndSection': 431, 'text': 'The umbrella term MND refers to diseases which cause the progressive loss of upper and/or lower motor neurons and a subsequent decrease in motor ability such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31031583'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 391, 'text': 'Degeneration of motor neurons results in progressive muscle weakness, which underlies several debilitating neurological disorders including amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegias (HSP), and spinal muscular atrophy (SMA).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34204831'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 258, 'text': 'Motor neuron diseases (MNDs) are a group of neurodegenerative disorders with involvement of upper and/or lower motor neurons, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), progressive bulbar palsy, and primary lateral sclerosis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15372378'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 401, 'text': \"Motor neuron diseases may be divided into three categories: those with lower motor neuron involvement--spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA or Kennedy's disease); those with upper motor neuron involvement--primary lateral sclerosis (PLS) and the spastic paraplegias; and those with combined upper and lower motor neuron involvement--amyotrophic lateral sclerosis (ALS).\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14753656'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 220, 'text': 'Among the motor neuron diseases, three share the clinical features of prominent upper motor neuron signs--amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) and the hereditary spastic paraplegias (HSP).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16036421'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'Motor neuron diseases, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), share several clinical similarities while differing substantially in etiology, disease onset and progression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33374658'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 218, 'text': 'Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15384941'}]\n\n\n                 'Which are the motor neuron diseases?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Amyotrophic Lateral Sclerosis\", \"ALS\", \"Spinal Bulbar Muscular Atrophy\", \"SBMA\", \"Spinal Muscular Atrophy\", \"SMA\", \"hereditary spastic paraplegia\", \"HSP\", \"Primary lateral sclerosis\", \"PLS\", \"Progressive bulbar palsy\", \"PBP\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 122, 'offsetInEndSection': 310, 'text': 'Therapeutic plasma exchange (TPE) is the most common modality employed with the rationale of rapid reduction of a pathogenic substance distributed primarily in the intravascular compartmen', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33991255'}, {'offsetInBeginSection': 766, 'offsetInEndSection': 1056, 'text': 'Though therapeutic apheresis modalities are employed frequently in children with kidney disease, most experiences are extrapolated from adult studies. International and national registries need to be established to elucidate the role of apheresis modalities in children with kidney disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33991255'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 78, 'text': 'Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1)', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551087'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 79, 'text': 'Fulminant Hepatic Failure in Dengue Fever Without Plasma Leakage: A Case Report', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35547461'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 96, 'text': 'Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551628'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 196, 'text': 'Recently, a randomized controlled trial (RCT) demonstrated rapid but individually variable hemodynamic improvement with therapeutic plasma exchange (TPE) in patients with septic shock.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35551628'}, {'offsetInBeginSection': 14, 'offsetInEndSection': 145, 'text': 'Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35689538'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 85, 'text': 'Role of Therapeutic Plasmapheresis in SARS-CoV-2 Induced Cytokine Release Syndrome: A', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35585996'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 233, 'text': 'Background: Cytokine release syndrome (CRS) significantly contributes to the pathophysiology and progression of COVID-19. It is speculated that therapeutic plasma exchange (TPE) can dampen CRS via elimination of pathogenic cytokines.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35585996'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 175, 'text': 'Successful therapeutic plasma exchange in a case with extremely severe hypertriglyceridemia secondary to diabetic ketoacidosis concomitant with type IX glycogen storage diseas', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34690074'}, {'offsetInBeginSection': 9, 'offsetInEndSection': 91, 'text': 'Therapeutic plasma exchange (TPE) is a treatment option to reduce thyroid hormones', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35963982'}, {'offsetInBeginSection': 1, 'offsetInEndSection': 63, 'text': 'herapeutic plasma exchange in hyperthyroidism prior to surgery', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35963982'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 112, 'text': 'Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35353437'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 116, 'text': 'Optic neuritis (ON) causes several sequela. Aggressive treatment with plasma exchange (TPE) is an option', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35353437'}, {'offsetInBeginSection': 188, 'offsetInEndSection': 295, 'text': ' We recruited adults with ON in neuromyelitis optica spectrum disorders (NMOSD) patients treated with TPE. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35353437'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 58, 'text': 'Total Plasma Exchange in Neuromuscular Junction Disorders-', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35955999'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 300, 'text': 'Total plasma exchange (TPE) has proven efficacy in NJD', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35955999'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 102, 'text': 'Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34904748'}, {'offsetInBeginSection': 12, 'offsetInEndSection': 406, 'text': 'Therapeutic plasma exchange (TPE) and immunoadsorption (IA) are first or second line treatment options in patients with neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders (NMSOD), chronic inflammatory demyelinating polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barr\u00e9 syndrome), and autoimmune encephalitis', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34904748'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Therapeutic plasma exchange (TPE) has been used for the treatment of neurologic diseases in which autoimmunity plays a major role.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17224307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'Therapeutic plasma exchange (TPE) has been used extensively for over 2 decades to treat a variety of autoimmune and congenital diseases and is now widely accepted.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10619926'}, {'offsetInBeginSection': 106, 'offsetInEndSection': 191, 'text': 'TPE is commonly used in neurological disorders where autoimmunity plays a major role.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28194064'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Therapeutic plasma exchange (TPE) is commonly used in many neurological disorders where an immune etiology was known or suspected.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18331814'}, {'offsetInBeginSection': 1730, 'offsetInEndSection': 1837, 'text': 'In conclusion; Therapeutic plasma exchange is an effective treatment option in several neurologic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 183, 'text': 'INTRODUCTION: Therapeutic plasma exchange (TPE) is commonly used as treatment of certain autoimmune neurological diseases (ANDs), and its main objective is the removal of pathogenic a', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32802495'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 165, 'text': 'Therapeutic plasma exchange (TPE) is used in the treatment of neurological, hematological, renal and autoimmune diseases with known or suspected immune pathogenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29882008'}, {'offsetInBeginSection': 132, 'offsetInEndSection': 302, 'text': 'TPE has an increasing list of indications in recent years such as neurological, connective tissue, hematological, nephrological, endocrinological and metabolic disorders.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 303, 'offsetInEndSection': 407, 'text': 'We report our multicenter data about therapeutic plasma exchange in patients with neurological diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 103, 'text': 'Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619327'}, {'offsetInBeginSection': 1337, 'offsetInEndSection': 1506, 'text': 'TPE is an effective treatment in neurologic diseases in which autoimmunity plays an important role in pathogenesis, and it is safe when performed in experienced centers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17224307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17224307'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 95, 'text': 'Therapeutic plasma exchange (TPE) has been mainly used in the treatment of autoimmune diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30924130'}, {'offsetInBeginSection': 341, 'offsetInEndSection': 576, 'text': 'TPE is useful in autoimmune haematological, renal, rheumatic and neurological diseases, and is recommended for acute disorders, together with relapsed or worsened chronic diseases that are often unresponsive to conventional treatments.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30924130'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 211, 'text': 'Therapeutic plasma exchange (TPE) is a treatment administered with the aim of removing a pathogenic material or compound causing morbidity in a variety of neurologic, hematologic, renal, and autoimmune diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33884210'}, {'offsetInBeginSection': 253, 'offsetInEndSection': 427, 'text': 'Diseases that can be treated with TPE are classified into the following categories: (1) endocrinological, (2) neurological, (3) renal/rheumatological, and (4) haematological.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16382247'}, {'offsetInBeginSection': 571, 'offsetInEndSection': 1166, 'text': \"Moreover, TPE in kidney diseases, for instance: desensitization in renal transplantation(ABO compatible) (living donor)and desensitization in deceased donor, desensitization in renal transplantation(ABO incompatible) (living donor), thrombotic microangiopathy complement Mediated (Factor H autoantibodies), Focal segmental glomerulosclerosis(recurrent in transplanted kidney), ANCA-associated rapidly progressive glomerulonephritis(Dialysis dependence, DAH), Anti-Glomerular basement membrane disease Goodpasture's syndrome)(DAH,Dialysis-independence,) has been utilized as an initial treatment.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31029610'}, {'offsetInBeginSection': 157, 'offsetInEndSection': 265, 'text': ' For decades, therapeutic plasma exchange (TPE) is performed for the management of immune-mediated diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34261138'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Therapeutic plasma-exchange (TPE) is used as primary and adjunctive therapy in treatment of several hematologic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619323'}, {'offsetInBeginSection': 222, 'offsetInEndSection': 329, 'text': ' Successful treatment of aHUS with plasma infusions and therapeutic plasma exchange (TPE) is well reported.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24277990'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 86, 'text': 'Several neurologic disorders have been treated with therapeutic plasma exchange (TPE).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22277020'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 127, 'text': 'INTRODUCTION: Therapeutic plasma exchange (TPE) is the first-line treatment for acute thrombotic thrombocytopenic purpura (TTP)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32605805'}, {'offsetInBeginSection': 1093, 'offsetInEndSection': 1173, 'text': 'TPE is effectively and safely carried out in our center in hematologic diseases.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23619323'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 192, 'text': 'BACKGROUND: Therapeutic plasma exchange (TPE) is a conventional second-line treatment for patients with multiple sclerosis (MS) or clinically isolated syndrome with steroid-refractory relapses', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35302053'}, {'offsetInBeginSection': 674, 'offsetInEndSection': 986, 'text': 'As a supportive therapy, the plasma exchange was effective in the hyperviscosity syndrome, myasthenia gravis, thrombotic thrombocytopenic syndrome, myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), hypercholesterolaemia, Guillain-Barr\u00e9 Syndrome, haemolytic crisis of a homozygous sickle-cell anaemia.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1703815'}]\n\n\n                 'Treatment with plasma exchange (TPE) is used for what diseases'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"kidney disease\", \"melanoma\", \"cancer\", \"dengue fever\", \"Covid -19\", \"septic shock\", \"cytokine storm\", \"diabetic ketoacidosis concomitant with type IX glycogen storage disease (GSD)\", \"neuromyelitis optica spectrum disorders.\", \"Neuromuscular junction disorders (NJDs)\", \"Guillain-Barr\\u00e9 syndrome\", \"auto immune\", \"neurological disorders\", \"hematological disorders\", \"fulminant Hepatic failure\", \"Newcastle Disease\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 254, 'offsetInEndSection': 376, 'text': 'LS is a rare progressive multisystem fatal disorder inherited by autosomal recessive, X-linked and maternal transmission. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}, {'offsetInBeginSection': 587, 'offsetInEndSection': 1031, 'text': 'LS is due to a deficit of various respiratory chain and Krebs cycle enzymes resulting in insufficient production of adenosine triphosphate (ATP), in particular cytochrome-c-oxidase (COX), pyruvate carboxylase, pyruvate dehydrogenase complex and complex I of the respiratory chain, which share an autosomal recessive and X-linked mode of transmission. Cases with maternal inheritance (MILS) are due to a mitochondrial DNA (mtDNA) point mutation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24299589'}]\n\n\n                 'How is Leigh syndrome inherited?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"maternal inheritance\", \"mitochondrial DNA (mtDNA) point mutation\", \"MILS\", \"autosomal recessive\", \"X-linked\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 132, 'offsetInEndSection': 261, 'text': 'Zinner syndrome comprises triad of seminal vesicle cyst, unilateral renal agenesis and ipsilateral ejaculatory duct obstruction. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34584848'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 272, 'text': 'We present the case of a 51-year-old male with Zinner syndrome, which is a rare disease, resulting from an abnormal evolution of the mesonephric (Wolffian) duct. It consists in cystic dilations of one seminal vesicle and/or ejaculatory duct and ipsilateral renal agenesis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34527910'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'A rare triad of Wolffian duct anomaly known as Zinner syndrome includes unilateral renal agenesis with ipsilateral seminal vesicle cyst and ejaculatory duct obstruction.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34504629'}, {'offsetInBeginSection': 149, 'offsetInEndSection': 340, 'text': 'Zinner syndrome, first described in 1914, refers to a triad of features consisting of seminal vesicle cysts, ejaculatory duct obstruction, and unilateral (mostly ipsilateral) renal agenesis. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32991910'}, {'offsetInBeginSection': 220, 'offsetInEndSection': 335, 'text': 'The triad of SV cysts, ipsilateral renal agenesis and ejaculatory duct obstruction is known as the Zinner syndrome.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33462046'}]\n\n\n                 'List features of the Zinner syndrome.'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"seminal vesicle cyst\", \"unilateral renal agenesis\", \"ipsilateral ejaculatory duct obstruction\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 988, 'offsetInEndSection': 1755, 'text': ' There was low or moderate certainty evidence for a large (\u22652-fold) magnitude of association between hospitalisation in people with COVID-19, and: obesity class III, heart failure, diabetes, chronic kidney disease, dementia, age >45 years, male gender, black race/ethnicity (vs non-Hispanic white), homelessness and low income. Age >60\\u2009and >70 years may be associated with large increases in mechanical ventilation and severe disease, respectively. For mortality, a large magnitude of association may exist with liver disease, Bangladeshi ethnicity (vs British white), age >45 years, age >80 years (vs 65-69 years) and male gender among 20-64 years (but not older). Associations with hospitalisation and mortality may be very large (\u22655-fold) for those aged \u226560 years.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33986052'}, {'offsetInBeginSection': 1768, 'offsetInEndSection': 1864, 'text': 'Increasing age (especially >60 years) may be the most important risk factor for severe outcomes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33986052'}, {'offsetInBeginSection': 1108, 'offsetInEndSection': 1682, 'text': 'In multivariable logistic regression analyses, increasing age (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 1.1-1.2, p<0.001), male gender (aOR 1.8, 95% CI 1.2-2.7, p = 0.002), Hispanic ethnicity (aOR 1.9, 95% CI 1.2-3.1, p = 0.01), obesity (3.1, 95% CI 1.9-5.1, p<0.001), asthma history (aOR 2.3, 95% CI 1.3-4.0, p = 0.003), congestive heart failure (aOR 6.0, 95% CI 1.5-25.1, p = 0.01), cerebrovascular disease (aOR 4.9, 95% CI 1.7-14.7, p = 0.004), and diabetes (aOR 3.4, 95% CI 1.9-6.2, p<0.001) were predictive of severe disease diagnoses within 30 days.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34329347'}, {'offsetInBeginSection': 1417, 'offsetInEndSection': 2299, 'text': 'The strongest association with risk of severe disease after vaccination was age, which increased among patients aged 50 years or older with an adjusted odds ratio (aOR) of 1.42 (CI, 1.40-1.44) per 5-year increase in age, such that patients aged 80 years or older had an aOR of 16.58 (CI, 13.49-20.37) relative to patients aged 45 to 50 years. Immunocompromising conditions, including receipt of different classes of immunosuppressive medications (eg, leukocyte inhibitor: aOR, 2.80; 95% CI, 2.39-3.28) or cytotoxic chemotherapy (aOR, 2.71; CI, 2.27-3.24) prior to breakthrough infection, or leukemias or lymphomas (aOR, 1.87; CI, 1.61-2.17) and chronic conditions associated with end-organ disease, such as heart failure (aOR, 1.74; CI, 1.61-1.88), dementia (aOR, 2.01; CI, 1.83-2.20), and chronic kidney disease (aOR, 1.59; CI, 1.49-1.69), were also associated with increased risk.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36264571'}, {'offsetInBeginSection': 879, 'offsetInEndSection': 1332, 'text': 'Factors associated with severe COVID-19 were older age [adjusted relative risk (aRR) 1.78, 95% confidence interval (CI) 1.61-1.97; P < 0.0001], diabetes (aRR 2.00, 95% CI 1.20-3.32; P = 0.007), cardiovascular disease (aRR 2.53, 95% CI 1.53-4.17; P < 0.0001), malignancy (aRR 4.57, 95% CI 1.62-12.87; P = 0.004), surgery/trauma (aRR 23.98, 95% CI 10.35-55.57; P < 0.0001) and human immunodeficiency virus infection (aRR 4.24, 95% CI 1.55-11.61; P = 005).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33741488'}, {'offsetInBeginSection': 1302, 'offsetInEndSection': 1424, 'text': 'Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (P\\xa0<\\xa00.001; OR, 17.46; 95% CI, 4.22-72.13).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33713486'}, {'offsetInBeginSection': 21, 'offsetInEndSection': 112, 'text': 'Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33713486'}, {'offsetInBeginSection': 1701, 'offsetInEndSection': 1780, 'text': 'Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33713486'}, {'offsetInBeginSection': 925, 'offsetInEndSection': 1090, 'text': ' Older age, male sex, non-White race, Hispanic ethnicity, obesity, and a higher number of chronic conditions were associated with increased risk of severe infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34538426'}, {'offsetInBeginSection': 1261, 'offsetInEndSection': 1549, 'text': 'In particular, persons 0 to 44 years of age with cancer, chronic neurologic disorders, hematologic disorders, ischemic heart disease, and other endocrine disorders had a greater than 3-fold increased risk of severe infection compared with persons of the same age without those conditions.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34538426'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 50, 'text': 'Sleep apnoea is a risk factor for severe COVID-19.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33436406'}, {'offsetInBeginSection': 148, 'offsetInEndSection': 259, 'text': 'Various risk factors for a severe course, such as higher age, male gender and pre-existing illnesses are known.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36431276'}, {'offsetInBeginSection': 1433, 'offsetInEndSection': 1515, 'text': 'Males could at higher risk of developing severe symptoms of COVID-19 than females.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33050972'}, {'offsetInBeginSection': 1028, 'offsetInEndSection': 1129, 'text': 'COVID-19 severity was associated only with older age and cardiac disease, in a multivariate analysis.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34165257'}, {'offsetInBeginSection': 110, 'offsetInEndSection': 353, 'text': 'Age, gender, and comorbidities are known to be risk factors for severe COVID-19 but are generally considered independently without accurate knowledge of the magnitude of their effect on risk, potentially resulting in incorrect risk estimation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33592063'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 81, 'text': 'Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33368966'}, {'offsetInBeginSection': 173, 'offsetInEndSection': 302, 'text': ' This study aimed to clarify the association between nervous system diseases and severity or mortality in patients with COVID-19.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33583450'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 177, 'text': 'Health factors such as diabetes, severe obesity and chronic kidney disease are all associated with a more severe outcome following coronavirus disease 2019 (COVID-19) infection.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32878679'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 154, 'text': 'BACKGROUND: Lifestyle factors including obesity and smoking are suggested to be correlated with increased risk of COVID-19 severe illness or related death', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33536004'}, {'offsetInBeginSection': 1633, 'offsetInEndSection': 1851, 'text': 'There is no evidence supporting that NAFLD is a causal risk factor for severe COVID-19. Previous observational associations between NAFLD and COVID-19 are likely attributed to the correlation between NAFLD and obesity.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35124268'}]\n\n\n                 'What factors are associated with severe COVID-19?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"Older age\", \"Age (especially > 60 years)\", \"increasing age\", \"Obesity\", \"Chronic kidney disease\", \"Chronic neurologic disorders\", \"Dementia\", \"Diabetes mellitus\", \"Diabetes\", \"Cerebrovascular disease\", \"Heart failure\", \"Congestive heart failure\", \"Cardiovascular disease\", \"Ischemic heart disease\", \"Malignancy\", \"Cancer\", \"Human immunodeficiency virus infection\", \"HIV\", \"Surgery\", \"Trauma\", \"Hematologic disorders\", \"Immunocompromising conditions\", \"Immunosuppression\", \"Asthma\", \"Hispanic ethnicity\", \"African-American ethnicity\", \"Cirrhosis\", \"Male sex\", \"male gender\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 358, 'offsetInEndSection': 582, 'text': ' Non-pharmacological comfort measures such as breastfeeding, swaddling and sweet solutions are inconsistently implemented and are not always practical or effective in reducing the transmission of noxious input to the brain. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250332'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 400, 'text': \"In this comparative effectiveness research 195 neonates >36 weeks' gestation were randomised to three groups, receiving during heel stick: (i) breastfeeding, (ii) sucrose 24% liquid with non-nutritive sucking and (iii) sucrose 24% gel with non-nutritive sucking. \", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 470, 'offsetInEndSection': 537, 'text': 'All the methods analysed has shown to be effective in reducing pain', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 539, 'offsetInEndSection': 668, 'text': 'There was an increase in odds of pain following liquid sucrose compared to breastfeeding (OR\\u2009=\\u20091.60; 95% CI: 0.82-3.3; p\\u2009=\\u20090.17).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 861, 'offsetInEndSection': 999, 'text': 'Sucrose 24% gel with non-nutritive sucking seems to be a valid alternative when breastfeeding is not possible. Further research is needed.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33664472'}, {'offsetInBeginSection': 195, 'offsetInEndSection': 264, 'text': 'Oral sucrose is commonly given to children to reduce procedural pain.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31317627'}, {'offsetInBeginSection': 1508, 'offsetInEndSection': 1849, 'text': 'he present systematic review and meta-analyses demonstrate that glucose reduces pain scores and crying during single heel lances and venipunctures. Results indicate that 20% to 30% glucose solutions have analgesic effects and can be recommended as an alternative to sucrose for procedural pain reduction in healthy term and preterm neonates.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23748256'}]\n\n\n                 'What are the currently used non-pharmacological measures for the management of procedural pain in neonates?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"breastfeeding\", \"swaddling\", \"sweet solutions\", \"sucrose\", \"glucose\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 447, 'offsetInEndSection': 727, 'text': ' The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4), in the presence of a specific 4qA161 phenotype. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21496633'}]\n\n\n                 'Which are the types of Facioscapulohumeral Muscular Dystrophy?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"FSHD1\", \"FSHD2\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 0, 'offsetInEndSection': 104, 'text': 'Microphthalmia-associated transcription factor (MITF) is the master regulator of the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 568, 'offsetInEndSection': 940, 'text': 'MITF and SOX10 actively recruit BRG1 to a set of MITF-associated regulatory elements (MAREs) at active enhancers. Combinations of MITF, SOX10, TFAP2A, and YY1 bind between two BRG1-occupied nucleosomes thus defining both a signature of transcription factors essential for the melanocyte lineage and a specific chromatin organisation of the regulatory elements they occupy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 153, 'text': 'MITF governs multiple steps in the development of melanocytes, including specification from neural crest, growth, survival, and terminal differentiation.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649789'}, {'offsetInBeginSection': 298, 'offsetInEndSection': 331, 'text': 'However, MITF does not act alone.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649789'}, {'offsetInBeginSection': 427, 'offsetInEndSection': 982, 'text': 'ChIP-seq studies have indicated that the transcription factors SOX10, YY1, and TFAP2A co-occupy subsets of regulatory elements bound by MITF in melanocytes. Analyses at single loci also support roles for LEF1, RB1, IRF4, and PAX3 acting in combination with MITF, while sequence motif analyses suggest that additional transcription factors colocalize with MITF at many melanocyte-specific regulatory elements. However, the precise biochemical functions of each of these MITF collaborators and their contributions to gene expression remain to be elucidated.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28649789'}, {'offsetInBeginSection': 682, 'offsetInEndSection': 940, 'text': 'Combinations of MITF, SOX10, TFAP2A, and YY1 bind between two BRG1-occupied nucleosomes thus defining both a signature of transcription factors essential for the melanocyte lineage and a specific chromatin organisation of the regulatory elements they occupy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 169, 'text': 'The microphthalmia-associated transcription factor (Mitf) is essential for melanocytic lineage development and for expression of melanogenic enzymes, such as tyrosinase.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11830592'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 190, 'text': 'Mitf encodes a basic helix-loop-helix transcription factor that plays an essential role in the differentiation of the retinal pigmented epithelium (RPE) and neural crest-derived melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15277526'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 142, 'text': 'Commitment to the melanocyte lineage is characterized by the onset of expression of the microphthalmia-associated transcription factor (Mitf).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17000761'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 163, 'text': 'The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12789278'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 135, 'text': 'Commitment to the melanocyte lineage is characterized by the onset of microphthalmia-associated transcription factor (Mitf) expression.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10770922'}, {'offsetInBeginSection': 462, 'offsetInEndSection': 567, 'text': 'BRG1 is essential for melanoma cell proliferation in vitro and for normal melanocyte development in vivo.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 117, 'text': 'Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells.', 'beginSection': 'title', 'endSection': 'title', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 1001, 'offsetInEndSection': 1090, 'text': 'MITF-BRG1 interplay thus plays an essential role in transcription regulation in melanoma.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25803486'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 372, 'text': \"The basic helix-loop-helix microphthalmia transcription factor (MITF) is the master regulator determining the identity and properties of the melanocyte lineage, and is regarded as a lineage-specific 'oncogene' that has a critical role in the pathogenesis of melanoma.\", 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21258399'}, {'offsetInBeginSection': 273, 'offsetInEndSection': 529, 'text': 'MITF regulates expression of numerous pigmentation genes to promote melanocyte differentiation, as well as fundamental genes for maintaining cell homeostasis, including genes encoding proteins involved in apoptosis (eg, BCL2) and the cell cycle (eg, CDK2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28263292'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'During embryogenesis, the transcription factor, Sox10, drives the survival and differentiation of the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23935512'}, {'offsetInBeginSection': 199, 'offsetInEndSection': 352, 'text': 'MITF encodes a transcription factor that is essential for normal melanocyte development and appears to regulate expression of several pigmentation genes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12819038'}, {'offsetInBeginSection': 324, 'offsetInEndSection': 547, 'text': 'Mitf is a basic helix-loop-helix-leucine zipper transcription factor whose M isoform is restricted to neural crest derived melanocytes and is essential for the development of these cells in vertebrates from mammals to fish.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14660543'}, {'offsetInBeginSection': 826, 'offsetInEndSection': 990, 'text': ' In melanocytes, studies have so far focused on the Sox10 protein which functions both during melanocyte specification and at later times in the melanocyte lineage.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15760336'}, {'offsetInBeginSection': 121, 'offsetInEndSection': 288, 'text': ' However, the molecular mechanisms by which SOX10 guides the appropriate gene expression programs necessary to promote the melanocyte lineage are not fully understood.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26206884'}, {'offsetInBeginSection': 475, 'offsetInEndSection': 630, 'text': ' SMARCA4 is also required for development of multipotent neural crest precursors into melanoblasts, which differentiate into pigment-producing melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36112085'}, {'offsetInBeginSection': 990, 'offsetInEndSection': 1090, 'text': ' During specification, Sox10 activates the Mitf gene as the key regulator of melanocyte development.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15760336'}, {'offsetInBeginSection': 953, 'offsetInEndSection': 1084, 'text': ' MITF directs the terminal differentiation of melanocytes, and PAX3 helps to establish the properties of the melanocyte stem cells.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22999738'}, {'offsetInBeginSection': 473, 'offsetInEndSection': 616, 'text': ' Functionally, Tfap2b is required for only a few late-stage embryonic melanocytes, and is essential for McSC-dependent melanocyte regeneration.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35021087'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 314, 'text': 'Here, by screening a pool of candidate transcription factors, we identify that a combination of the three factors, MITF, SOX10 and PAX3, directly converts mouse and human fibroblasts to functional melanocytes.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25510211'}]\n\n\n                 'Which transcription factors are essential for the melanocyte lineage?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"MITF\", \"Microphthalmia-associated transcription factor\", \"SOX10\", \"TFAP2A\", \"YY1\", \"IRF4\", \"PAX3\", \"RB1\", \"LEF1\", \"BRG1\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 121, 'offsetInEndSection': 188, 'text': '8% of female DMD carriers have muscle weakness and cardiomyopathy. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32022138'}, {'offsetInBeginSection': 820, 'offsetInEndSection': 982, 'text': 'Pseudohypertrophy of calf muscles, muscular weakness, compensatory movements and longer timed performance on functional tasks were observed in most of the cases. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32022138'}, {'offsetInBeginSection': 1465, 'offsetInEndSection': 1686, 'text': 'Clinical manifestation of asymmetrical muscle weakness and compensatory movements, or both can be found in female carriers of DMD mutations, which can adversely affect posture and functional performance of these patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32022138'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'BACKGROUND: Female carriers of Duchenne muscular dystrophy (DMD), although usually asymptomatic, develop muscle weakness up to 17% of the time, and a third present cardiac abnormalities or cognitive', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26718981'}, {'offsetInBeginSection': 672, 'offsetInEndSection': 789, 'text': 'The symptomatic females shared mild but progressive muscular weakness and increased serum creatin kinase (CK) levels.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24135430'}, {'offsetInBeginSection': 105, 'offsetInEndSection': 240, 'text': 'Approximately 8% of female Duchenne muscular dystrophy (DMD) carriers are manifesting carriers and have muscle weakness to some extent.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21155054'}, {'offsetInBeginSection': 499, 'offsetInEndSection': 688, 'text': 'Two to 20% of female heterozygotes with a P/LP variant develop symptoms of dystrophinopathy ranging from mild muscle weakness to significant disability similar to Becker muscular dystrophy.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36152336'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 198, 'text': 'Female carriers of Duchenne muscular dystrophy (DMD) presenting with DMD symptomology similar to males with DMD, such as skeletal muscle weakness and cardiomyopathy, are termed manifesting carriers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33788896'}, {'offsetInBeginSection': 166, 'offsetInEndSection': 289, 'text': 'ales. Female DMD/BMD carriers (DMDc/BMDc) are mostly free of skeletal muscle symptoms, but they are also prone to cardiomyo', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26113120'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 134, 'text': 'Female carriers of mutations in the dystrophin gene (DMD-carriers) may manifest clinically in the skeletal muscle, the heart, or both.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29862154'}, {'offsetInBeginSection': 520, 'offsetInEndSection': 600, 'text': 'Cardiomyopathy is sometimes the only clinical symptom in female carriers of DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10674846'}, {'offsetInBeginSection': 137, 'offsetInEndSection': 289, 'text': ' Cardiomyopathy is common and often prevalent at similar frequency in female DMD carriers irrespective of whether they manifest skeletal muscle disease.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32762558'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 119, 'text': 'Female carriers of DMD gene mutations may be symptomatic and show variable skeletal as well as cardiac muscle symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31326192'}, {'offsetInBeginSection': 519, 'offsetInEndSection': 600, 'text': ' Cardiomyopathy is sometimes the only clinical symptom in female carriers of DMD.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10674846'}, {'offsetInBeginSection': 553, 'offsetInEndSection': 633, 'text': ' Our findings show abnormal muscle energy metabolism in DMD/BMD female carriers.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1557082'}, {'offsetInBeginSection': 220, 'offsetInEndSection': 329, 'text': ' DMD/BMD female carriers are usually asymptomatic, although about 8\\xa0% may exhibit muscle or cardiac symptoms.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27098336'}, {'offsetInBeginSection': 973, 'offsetInEndSection': 1123, 'text': ' mutations were found. 28 (22%) women had symptoms. 22 (17%) had muscle weakness, varying from mild to moderately severe. Muscle weakness was found in', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10382696'}]\n\n\n                 'What are common symptoms in female carriers of DMD?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"muscle weakness\", \"asymmetrical muscle weakness\", \"cardiomyopathy\", \"longer timed performance on functional tasks\", \"compensatory movements\", \"Pseudohypertrophy of calf muscles\"]}"}]}
{"messages": [{"role": "system", "content": "You are BioASQ-GPT, an AI expert in question answering, research, and information retrieval in the biomedical domain."}, {"role": "user", "content": " [{'offsetInBeginSection': 467, 'offsetInEndSection': 699, 'text': 'There are four types: CMT1, CMT2, CMT3 and CMT4, depending upon the involvement of specific gene deficit, inheritance pattern, age of onset and whether the primary defect results in an abnormality of the myelin or axon of the nerve.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34540429'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 268, 'text': 'Clinically, CMT can be divided into two main types: a demyelinating type (CMT1, CMT3, CMT4 and CMTX1) and an axonal type (CMT2)', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24846915'}, {'offsetInBeginSection': 467, 'offsetInEndSection': 740, 'text': ' CMT1, or hypertrophic form in which mutations or a duplication were found on chromosome 17 is the most frequent (CMT1A), CMT2 is the neuronal form, CMT3 is termed the Dejerine-Sottas disease, CMT4 recessive forms, CMT5 a form with associated pyramidal features, and CMTX. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9686263'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 375, 'text': 'Charcot-Marie-Tooth (CMT) is a group of inherited diseases clinically and genetically heterogenous, characterised by length dependent degeneration of axons of the peripheral nervous system. A missense mutation (p.R158H) in the pyruvate dehydrogenase kinase 3 gene (PDK3) has been identified as the genetic cause for an X-linked form of CMT (CMTX6) in two unrelated families. ', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32504000'}, {'offsetInBeginSection': 571, 'offsetInEndSection': 697, 'text': 'The subdivision into demyelinating CMT1 and axonal CMT2 types was a milestone and is still valid for the majority of patients.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16775364'}, {'offsetInBeginSection': 752, 'offsetInEndSection': 895, 'text': 'Intermediate conduction velocities are often found in males with X-linked CMT (CMTX), and different intermediate CMT types have been identified', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16775364'}, {'offsetInBeginSection': 246, 'offsetInEndSection': 408, 'text': 'The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24198383'}, {'offsetInBeginSection': 409, 'offsetInEndSection': 482, 'text': 'Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24198383'}, {'offsetInBeginSection': 189, 'offsetInEndSection': 439, 'text': 'Mutations of the gene encoding mitofusin 2 (MFN2) have recently been identified as the cause of approximately one-third of dominantly inherited cases of the axonal degenerative forms of Charcot-Marie-Tooth disease (CMT type 2A) and of rarer variants.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20163430'}, {'offsetInBeginSection': 440, 'offsetInEndSection': 641, 'text': 'The latter include a severe, early-onset axonal neuropathy, which may occur in autosomal dominant or recessive forms, as well as some instances associated with pyramidal tract involvement (CMT type 5),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20163430'}, {'offsetInBeginSection': 642, 'offsetInEndSection': 674, 'text': 'with optic atrophy (CMT type 6),', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20163430'}, {'offsetInBeginSection': 310, 'offsetInEndSection': 481, 'text': 'Two principal forms of Charcot-Marie-Tooth (CMT) disease have been distinguished: CMT 1, corresponding to a demyelinating type, and CMT 2, corresponding to an axonal type.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12901697'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 214, 'text': 'Charcot-Marie-Tooth disease (CMT), the most common inherited peripheral neuropathy, is a progressive sensorimotor neuropathy divided into types 1 and 2 based upon electrophysiologic and neuropathologic differences.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1549221'}, {'offsetInBeginSection': 435, 'offsetInEndSection': 583, 'text': 'Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form, exhibiting autosomal dominant inheritance and linkage to chromosome 17p11.2p12.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8128981'}, {'offsetInBeginSection': 517, 'offsetInEndSection': 674, 'text': 'Recent work has identified the gene products corresponding to CMT1A, CMT1B and CMTX as peripheral myelin protein-22(PMP22), Po and connexin 32, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8810804'}, {'offsetInBeginSection': 581, 'offsetInEndSection': 822, 'text': 'A systematic computer-based literature search was conducted on PubMed, using the following MeSH: (1) intermediate Charcot-Marie-Tooth; (2) X-linked intermediate Charcot-Marie-Tooth; and (3) X-linked Charcot-Marie-Tooth and electrophysiology.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28364294'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 130, 'text': 'Charcot-Marie-Tooth disease (CMT) has been classified into two types, CMT1 and CMT2, demyelinating and axonal forms, respectively.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15549395'}, {'offsetInBeginSection': 114, 'offsetInEndSection': 434, 'text': 'Two major types can be distinguished based on electrophysiologic phenotypes: CMT type 1 (CMT1) displays uniformly decreased nerve conduction velocity associated with a demyelinating hypertrophic neuropathy, and CMT type 2 (CMT2) displays normal or near-normal nerve conduction velocity associated with a neuronal defect.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8128981'}, {'offsetInBeginSection': 141, 'offsetInEndSection': 269, 'text': 'Clinically, CMT can be divided into two main types: a demyelinating type (CMT1, CMT3, CMT4 and CMTX1) and an axonal type (CMT2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24846915'}, {'offsetInBeginSection': 142, 'offsetInEndSection': 341, 'text': 'Common clinical manifestations of CMTX, as in other forms of Charcot-Marie-Tooth disease (CMT), are distal muscle wasting and weakness, hyporeflexia, distal sensory disturbance, and foot deformities.', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12185164'}, {'offsetInBeginSection': 0, 'offsetInEndSection': 121, 'text': 'Charcot-Marie-Tooth disease (CMT) has been classified into two types: demyelinating forms (CMT1) and axonal forms (CMT2).', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17437620'}, {'offsetInBeginSection': 426, 'offsetInEndSection': 576, 'text': 'y known to affect 1 in 2500 individuals. There are four types: CMT1, CMT2, CMT3 and CMT4, depending upon the involvement of specific gene deficit, inh', 'beginSection': 'abstract', 'endSection': 'abstract', 'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34540429'}]\n\n\n                 'Which are the types of Charcot-Marie-Tooth Disease (CMT)?'. \n                 Answer this question by only returning a JSON string array called 'entities of entity names, numbers, or similar short expressions that are an answer to the question \n                 (e.g., the most common symptoms of a disease). The returned array will have to contain no more than 100 entries of no more than 100 characters each. If you don't know any answer return an empty array. \n                 Return only this array, it must not contain phrases and **must be valid JSON**. Example: {\"entities\": [\"entity1\", \"entity2\"]}"}, {"role": "assistant", "content": "{\"entities\": [\"CMT1\", \"CMT1A\", \"CMT2\", \"CMT type 2A\", \"CMT3\", \"CMT4\", \"CMT5\", \"CMT type 5\", \"CMTX\", \"CMTX1\", \"CMTX6\", \"CMT6\", \"CMT type 6\"]}"}]}
